

# Reversing Immunosenescence with Senolytics to Enhance Tumor

## Immunotherapy

Niu Liu<sup>1,2,3#</sup>, Jiaying Wu<sup>1,2#</sup>, Enze Deng<sup>4,5#</sup>, Jianglong Zhong<sup>1,2#</sup>, Bin Wei<sup>1,2#</sup>, Tingting Cai<sup>1,2#</sup>, Xiaohui Duan<sup>6</sup>, Sha Fu<sup>7</sup>, David O. Osei-Hwedieh<sup>8</sup>, Ou Sha<sup>9</sup>, Yunsheng Chen<sup>1,2,3</sup>, Xiaobin Lv<sup>10</sup>, Yingying Zhu<sup>11</sup>, Lizao Zhang<sup>1,2</sup>, Hsinyu Lin<sup>1,2</sup>, Qunxing Li<sup>1,2</sup>, Peichia Lu<sup>1,2</sup>, Jiahao Miao<sup>1,2,3</sup>, Teppei Yamada<sup>12</sup>, Lei Cai<sup>13</sup>, Hongwei Du<sup>14</sup>, Sylvan C. Baca<sup>8</sup>, Qingpei Huang<sup>4</sup>, Soldano Ferrone<sup>†</sup>, Xinhui Wang<sup>15\*</sup>, Fang Xu<sup>3,16,17\*</sup>, Xiaoying Fan<sup>4,18\*</sup>, Song Fan<sup>1,2\*</sup>

### Affiliations:

<sup>1</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital; Guangzhou, 510120, China.

<sup>2</sup>Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Guangzhou, 510120, China.

<sup>3</sup>Interdisciplinary Center for Brain Information, Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

<sup>4</sup>Guangzhou National Laboratory, Guangzhou International Bio Island; Guangzhou, 510005, China.

<sup>5</sup>MOE Key Laboratory of Gene Function and Regulation, Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University; Guangzhou, 510275, China.

22 <sup>6</sup>Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University;  
23 Guangzhou, 510120, China.

24 <sup>7</sup>Department of Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital,  
25 Sun Yat-Sen University; Guangzhou, 510120, China.

26 <sup>8</sup>Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, 02215, USA.

27 <sup>9</sup>School of Dentistry, Shenzhen University Medical School; Shenzhen, 518037, China.

28 <sup>10</sup>Jiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical  
29 College, Nanchang University; Nanchang, 330008, China.

30 <sup>11</sup>Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial  
31 Hospital, Sun Yat-sen University; Guangzhou, 510120, China.

32 <sup>12</sup>Lecturer, Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka  
33 University; Fukuoka, 814-0180, Japan.

34 <sup>13</sup>Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing  
35 University; Chongqing, 400038, China.

36 <sup>14</sup>Cancer Institute, Xuzhou Medical University; Xuzhou, 221004, China.

37 <sup>15</sup>Department of Surgery, Massachusetts General Hospital, Harvard Medical School; Boston,  
38 02115, USA.

39 <sup>16</sup>Faculty of Life and Health Sciences, Shenzhen University of Advanced Technology;  
40 Shenzhen, 518107, China.

41 <sup>17</sup>Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced  
42 Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

43 <sup>18</sup>GMU-GIBH Joint School of Life Sciences, The Fifth Affiliated Hospital of Guangzhou  
44 Medical University, Guangzhou Medical University; Guangzhou, 510005, China.

45

46

47 \* Corresponding author. Email:

48 XWANG30@mgh.harvard.edu (X.W.); fang.xu@siat.ac.cn (F.X.);

49 fan\_xiaoying@gzlab.ac.cn (X.F.); fansong2@mail.sysu.edu.cn (S.F.).

50 # These authors contributed equally to this work.

51 † Deceased 10 January 2023.

52

53

54 **Abstract: Recent advancements in cancer immunotherapy have improved patient**  
55 **outcomes, yet responses to immunotherapy remain moderate. We conducted a Phase II**  
56 **clinical trial (NCT04718415) involving 51 cancer patients undergoing neoadjuvant**  
57 **chemoimmunotherapy and applied single-cell RNA and T/BCR sequencing on tumor and**  
58 **blood samples to elucidate the immune cell perturbations. Our findings associate poor**  
59 **response with reduced levels of CCR7<sup>+</sup>CD4 Naïve T cells and CD27<sup>+</sup> Memory B cells, as**  
60 **well as higher expression of immunosenescence-related genes in T and B cell subsets. Using**  
61 **naturally aged and *Ercc1*<sup>+/-</sup> transgenic aging mouse models, we found that senolytics**  
62 **enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating**  
63 **tumor immunosenescence. Notably, we launched a Phase II clinical trial, COIS-01**  
64 **(NCT05724329), which pioneers the combination of senolytics with anti-PD-1 therapy. The**

65 **clinical results demonstrate that this therapeutic strategy is associated with a favorable**  
66 **safety profile and therapeutic efficacy, significantly mitigating adverse effects and**  
67 **alleviating immunosenescence. These findings underscore the pivotal role of**  
68 **immunosenescence characteristics in influencing the effectiveness of immunotherapy and**  
69 **suggest a promising therapeutic efficacy along with a beneficial safety assessment for the**  
70 **combination of senolytics with anti-PD-1 therapy.**

71 **Main Text:**

72 Despite recent advancements in blocking the PD-1/PD-L1 pathway, which have  
73 revolutionized the treatment of solid tumors, only a small fraction of patients benefits from  
74 immunotherapy, with fewer than 20% showing sustained responses<sup>1-3</sup>. A major challenge in  
75 current immunotherapy and neoadjuvant strategies is our limited understanding of the highly  
76 dynamic and heterogeneous tumor immune microenvironment (TIME), which impacts treatment  
77 responses<sup>4-6</sup>. The concept of cancer immunoediting emphasizes the immune system's dual role  
78 in inhibiting tumor growth and shaping tumor immunogenicity. This process is described in three  
79 stages: elimination, equilibrium, and escape. During the elimination phase, the host's innate and  
80 adaptive immune systems recognize and respond to tumor-specific antigens<sup>7,8</sup>. T cells are the  
81 primary players in tumor immunity. Although tumor-reactive T cells are present in TIME, the  
82 phenotypic heterogeneity of T cells across different tumors and their divergent differentiation  
83 fates remain significant. Exhaustion still poses a major limitation to their anti-tumor potential  
84<sup>9,10</sup>.

85 Immunosenescence, a well-established phenomenon occurring with age, results in the  
86 immune system losing its ability to effectively respond to pathogens and cancer cells<sup>11-15</sup>.  
87 Recent studies have uncovered the complex role of immunosenescence in tumors, with factors

88 such as cAMP, glucose competition, and oncogenic stress in the TIME inducing senescence in T  
89 cells, macrophages, natural killer (NK) cells, and dendritic cells, thereby impairing their immune  
90 cytotoxic function against tumors<sup>16</sup>. However, it remains unclear whether individual differences  
91 in immunosenescence affect the efficacy of immunotherapy in cancer patients.

92 Previous studies have shown that blocking DNA damage signals can inhibit the senescence of  
93 tumor-infiltrating T cells, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs)  
94 against tumors<sup>17</sup>. Recent research also indicate that chronic inflammation caused by an aging  
95 immune system can promote cancer development, regardless of the age of the cancerous or  
96 surrounding tissues<sup>18</sup>. Therefore, we believe that the senescence status of immune cell  
97 subpopulations, which play a crucial role in tumor immunity, may be critical for treatment  
98 outcomes. We hypothesize that senolytics can be combined with ICIs to enhance their efficacy in  
99 treating solid tumors.

100 In this study, we first explored the variability in patient responses to neoadjuvant  
101 immunotherapy, starting with a Phase II clinical trial in head and neck squamous cell carcinoma  
102 (HNSCC, NCT04718415). Further analysis of single-cell RNA sequencing (scRNA-Seq) data  
103 from these patients allowed us to identify key immune cell subpopulations that influence  
104 immune responses and to reveal the negative impact of immunosenescence on immunotherapy  
105 efficacy. Additionally, animal study data highlighted the potential benefits of combining  
106 senolytics with ICIs for treating solid tumors, including HNSCC, bladder cancer, and breast  
107 cancer. We then initiated a pioneering Phase II clinical trial (COIS-01, NCT05724329) to  
108 evaluate the efficacy and safety of combining anti-aging drugs with ICIs in HNSCC patients.  
109 Our results indicate that the neoadjuvant combination of senolytics and ICIs significantly reduces  
110 toxic side effects compared to neoadjuvant chemotherapy. Furthermore, patients receiving the  
111 combination therapy exhibited a higher proportion of CCR7<sup>+</sup> naïve T cells within their tumors,

112 suggesting a mitigation of immunosenescence and an enhancement of the adaptive immune  
113 response.

114 **Phase II trial evaluating neoadjuvant chemotherapy combined with immunotherapy for**  
115 **oral cavity and oropharyngeal squamous cell carcinoma (OOC-001)**

116 We enrolled 51 patients with stage II-IVA HNSCC for neoadjuvant chemoimmunotherapy  
117 (OOC-001, NCT04718415). One patient was excluded from the evaluation due to refusing to  
118 continue the treatment (Extended Data Fig. 1a). All patients underwent a minimum of two cycles  
119 of neoadjuvant treatment, with 24 (47.1%) receiving 2 cycles, 23 (45.1%) receiving 3 cycles, and  
120 4 (7.8%) receiving 4 cycles of neoadjuvant treatment (Supplementary Tables 1-4). Among the 48  
121 evaluable patients, 23 patients achieved pathological complete response (pCR, 47.9%), 8 patients  
122 achieved major pathological response (MPR, 16.7%), 10 patients showed partial pathological  
123 response (pPR, 20.8%), and 7 patients displayed pathological no response (pNR, 14.6%) (Fig. 1a,  
124 Extended Data Fig. 1b). The comparison of radiologic and pathologic response indicators  
125 suggested that certain patients were pathologically assessed as pCR while radiologically assessed  
126 as PR (Partial response)/SD (Stable disease), highlighting significant inconsistency between  
127 pathological and radiological assessments (Fig. 1b). Compared to the baseline, 72.7% of primary  
128 tumors exhibited shrinkage, while only 46.7% of patients showed regression in lymph nodes,  
129 possibly indicating that primary tumors in HNSCC are more sensitive to neoadjuvant therapy  
130 (Fig. 1c and Extended Data Fig. 1c-e). Regarding treatment cycles, pathological assessment  
131 suggested that the efficacy of the 2-cycle treatment might be less than that of 3 or 4 cycles  
132 (Extended Data Fig. 1f). 48 patients (94%) experienced at least one treatment-related adverse  
133 effect (TRAE). Grade 3-4 TRAEs were observed in 26 patients (51%), and the most common  
134 TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea (49%) (Supplementary Table  
135 2).

136 The 24-month overall survival (OS) for the cohort was 93.9% (Extended Data Fig. 1g, h).  
137 Our findings show that combining sintilimab with carboplatin and nab-paclitaxel resulted in  
138 manageable side effects and achieved a high overall response rate (64.6%, MPR and pCR).  
139 Considering the trade-off between anti-tumor effectiveness and adverse effects, we observed that  
140 a 3-cycle treatment regimen offered superior benefits for patients with HNSCC.

### 141 **Immune landscape of HNSCC patients with neoadjuvant chemoimmunotherapy**

142 ScRNA-Seq and scT/BCR-Seq was performed in seven treatment-naïve tumor samples and  
143 nine blood samples (including pre-and post-treatment) (Fig. 1d, Supplementary Table 3).  
144 Following quality filtering, we obtained scRNA-Seq profiles as well as TCR and BCR  
145 clonotypes from 143,056 cells, encompassing T cells, NK cells, B cells, myeloid cells,  
146 fibroblasts, endothelium, and tumor cells (Supplementary Figure 1a-f). A total of 27 cell clusters  
147 with distinct molecular features were observed by re-clustering each major immune cell type  
148 (Fig. 1e).

149 We analyzed the abundance of various immune subtypes and compared their proportions  
150 across the tumor, pre-treatment blood (P0) and post-treatment blood (P1) of MPR and noMPR  
151 patients. The proportion of CD4<sup>+</sup> T cells showed the largest elevation among all immune cell  
152 types when comparing P1 to P0 (Supplementary Figure 1g, h). While compared to noMPR  
153 patients, MPR patients' tumors exhibited higher proportions of CCR7<sup>+</sup>CD4 Naïve T cells,  
154 CXCL13<sup>+</sup>CD4 T cells, GZMK<sup>+</sup>CD8 Tem cells, and CD27<sup>+</sup> Memory B cells. Conversely, the  
155 proportions of FOXP3<sup>+</sup>CD4 Treg cells and IGF1<sup>+</sup> macrophages (IGF1<sup>+</sup> Mφ) were lower (Fig. 1f  
156 and Supplementary Figure 2, 3a-f). The upregulated genes in noMPR patients of the main T/B  
157 cell subtypes were involved in aging-related pathways, indicating these pathways may contribute  
158 to variations in the treatment response status of HNSCC patients. (Supplementary Figure 3g,

159 Supplementary Table 5). Using T/BCR diversity as markers of antigenic immune responses to  
160 neoadjuvant therapy, we investigated TCR and BCR clonality in MPR and noMPR groups  
161 through three different methods (Chao1, Shannon Index, and Richness). The results showed that  
162 MPR patients exhibited higher TCR and BCR clonal diversity in CCR7<sup>+</sup>CD4 Naïve T cells,  
163 CXCL13<sup>+</sup>CD4 T cells, GZMK<sup>+</sup>CD8 Tem cells, and CD27<sup>+</sup> Memory B cells (Fig. 1g and  
164 Supplementary Figure 3h). Additionally, dominant clones present in the tumor and blood before  
165 treatment persisted as the dominant clones after treatment in MPR patients (Extended Data Fig.  
166 2a-c). Further analysis of TCR/BCR clonotypes from P0, P1, and tumors revealed no significant  
167 differences in TCR/BCR clonotypes in blood before and after treatment, nor between MPR and  
168 noMPR patients. Interestingly, MPR patients exhibited a greater number of unique TCR/BCR  
169 clonotypes within tumors, suggesting a richer TCR/BCR clonal diversity (Extended Data Fig. 2d,  
170 e).

171 Immunosenescence refers to the decline in the immune system's ability to effectively  
172 respond to pathogens and cancer cells<sup>11</sup>. Recent studies have found that characteristics of  
173 immunosenescence include an imbalance in the proportion of naïve and memory T cells, a  
174 decrease in the number of TCR clones, and elevated levels of *p16<sup>INK4a</sup>* (also known as *CDKN2A*)  
175 and *p21<sup>CIP1</sup>* (*CDKN1A*) expression<sup>19,20</sup>. We then examined the expressions of the senescent  
176 markers, P16 and P21, by immunostaining in tumor tissues from two clinical trials conducted at  
177 our center (OOC-001 and REDUCTION-I, NCT05582265). The results revealed that the tumor  
178 microenvironment of noMPR patients exhibited higher levels of senescent features (Fig. 1h and  
179 Extended Data Fig. 2f). In summary, our data suggests that non-responsive patients to  
180 neoadjuvant treatment demonstrate dysregulation in immune cell proportions and an increase in  
181 senescent characteristics.



## 182 **T cell and B cell subtypes exhibiting senescent features influence the response to** 183 **immunotherapy**

184 Recent studies have shown that in late life, the aging individual's adaptive immune system  
185 exhibits dysfunction and increased autoimmunity, with T and B cell aging being a primary  
186 manifestation of immunosenescence<sup>21,22</sup>. However, there is no gold standard marker for defining  
187 the senescence of T and B cells<sup>23</sup>. To figure out this assumption, we first created an  
188 immunosenescence-associated gene set (IAGs) consists of 154 genes based on extensive scRNA-  
189 Seq datasets differentiating immune cells from young and elderly individuals (Extended Data Fig.  
190 3a, Supplementary Table 6). The IAGs were significantly enriched in the immune cells of elderly  
191 individuals in three independent scRNA-Seq datasets (GSE157007<sup>24</sup>, GSE141595<sup>25</sup> and  
192 PRJCA002856) (Fig. 2a and Extended Data Fig. 3b-d), indicating they could reflect human  
193 immunosenescence characteristics. Additionally, evaluating IAGs in scRNA-Seq datasets for  
194 HNSCC and triple-negative breast cancer (TNBC)<sup>26</sup> immunotherapies also revealed lower  
195 senescent scores in MPR patients compared to noMPR patients (Extended Data Fig. 3e).  
196 Subsequently, we used IAGs to score T cells and their subtypes, which revealed lower  
197 immunosenescence features in MPR patients with HNSCC (Fig. 2b and Extended Data Fig. 4a).  
198 Furthermore, we also identified senescent genes associated with T cells from the IAGs, which  
199 showed higher expression levels in multiple T cell subgroups of noMPR patients, with GO  
200 analysis revealed enrichment in pathways related to S100 protein binding (Fig. 2c and Extended  
201 Data Fig. 4b, c). Similar results were obtained from the TNBC dataset (Extended Data Fig. 4d-h).

202 Relative to noMPR patients, MPR patients exhibited lower  $V\alpha/\beta$  gene usage frequencies in  
203  $CCR7^+CD4$  T cells and  $FOXP3^+CD4$  Treg cells in both tumors and blood, consistent with  
204 previous findings (Extended Data Fig. 5a). Pseudotime analysis of immune cells revealed that  
205  $CD4^+$  T cell subsets in peripheral blood exhibit an early differentiation phenotype, while their

206 tumor counterparts show a more differentiated phenotype. Notably, MPR patients demonstrated  
207 differentiation towards CCR7<sup>+</sup>CD4 Naïve T cells and CXCL13<sup>+</sup>CD4 Th cells, maintaining T cell  
208 vitality and the potential to differentiate into various functional subtypes. In contrast, CD4<sup>+</sup> T  
209 cells in non-MPR patients tended to differentiate towards FOXP3<sup>+</sup>CD4 Tregs, leading to  
210 immunosenescence-related characteristics (Extended Data Fig. 5b-d).

211 Numerous T cells demonstrate shared clonotypes between tumors and blood. These clonal T  
212 cells in tumor showed elevated IAGs scores than those in blood, suggesting a higher level of  
213 senescent characteristics for the tumor-infiltrating T cells (Fig. 2d, e). Analysis of paired TCR  
214 data revealed a notable reduction of both unique and total clonotypes particularly in the  
215 CCR7<sup>+</sup>CD4 Naïve T cells in noMPR patients compared with MPR patients (Fig. 2f).  
216 Immunosenescence features are notably pronounced in B cells of noMPR patients, particularly in  
217 CD27<sup>+</sup> Memory B cells (Extended Data Fig. 6a-e). Pairwise analysis of T and B cell receptors  
218 and ligands revealed strong interactions between FOXP3<sup>+</sup>CD4 Treg cells and CXCL13<sup>+</sup>CD4 T  
219 helper cells with B cells (Extended Data Fig. 6f). This indicates that in MPR patients, the  
220 reduced number of FOXP3<sup>+</sup>CD4 Tregs and increased number of CXCL13<sup>+</sup>CD4 T helpers may  
221 exert their effects through interactions with B cells.

222 Through immunofluorescence staining, we confirmed that CD4<sup>+</sup> T cells and CD27<sup>+</sup>  
223 memory B cells expressing the senescent marker S100A11 were more abundant in noMPR  
224 patients, while no difference was observed in the number of S100A11<sup>+</sup>CD8 T cells between  
225 noMPR and MPR patients, suggesting senescent status of CD4 T cells critically modulate  
226 patients' response to neoadjuvant therapy (Fig. 2g and Extended Data Fig. 6g). Analysis of  
227 HNSCC Patients' data from the TCGA database found that patients with high expression of IAGs  
228 such as *S100A11*, *AREG*, *CALD1*, *CDKN1A*, and *CASP4* together with low CD4 Naïve T cell or  
229 memory B cell abundance had significantly worse prognosis than those with low expression of

230 senescent genes and high proportions of CD4 Naïve T cells or memory B cells (Fig. 2h and  
231 Supplementary Figure 4). T cells predict responses to immunotherapy more effectively in  
232 HNSCC patients, while in TNBC patients, B cells are more predictive (Fig. 2i). These analyses  
233 suggest that the IAGs we constructed were effective in distinguishing the immune cells of  
234 noMPR and MPR patients, and that lower expression levels of IAGs in CCR7<sup>+</sup>CD4 Naïve T and  
235 CD27<sup>+</sup> Memory B cells are associated with a positive treatment response.

### 236 **IGF1<sup>+</sup> Mφ induce senescent characteristics in T cells**

237 Innate immune cells play an important role in early tumor cell recognition and subsequent  
238 initiation of inflammation and antitumor responses. To investigate whether non-lymphocyte  
239 immune cells are involved in the immunosenescence phenotype observed in our study subjects,  
240 we analyzed the gene expression features of myeloid cells. IGF1<sup>+</sup> Mφ exhibited the highest  
241 differentiation score among all myeloid cell types according to pseudotime analysis (Extended  
242 Data Fig. 7a). The precursor cells of IGF1<sup>+</sup> Mφ in the blood are IL1B-CD14 cells, which showed  
243 significant changes in the MPR group before and after treatment. Interestingly, the proportion of  
244 IGF1<sup>+</sup> Mφ within tumors and IL1B-CD14 cells in blood were significantly higher in noMPR  
245 patients (Fig. 2j and Extended Data Fig. 7b-d). Additionally, IGF1<sup>+</sup> Mφ negatively correlated  
246 with CCR7<sup>+</sup>CD4 Naïve T cells and CD27<sup>+</sup> Memory B cells in tumors (Fig. 2k). We also  
247 examined the composition proportions of myeloid cell subtypes in TNBC patients and found that  
248 PR patients had a higher proportion of IGF1<sup>+</sup> Mφ compared to SD patients, consistent with our  
249 HNSCC results (Extended Data Fig. 7e, f). By scoring the expression of six major senescence-  
250 associated secretory phenotype (SASP) factors in HNSCC and TNBC, we found that IL1B-  
251 CD14 monocytes and IGF1<sup>+</sup> Mφ expressed higher levels of SASP factors compared to other  
252 myeloid cell subtypes (Extended Data Fig. 7g, h). Interaction analysis further revealed that  
253 IGF1<sup>+</sup> Mφ had a strong potential for interaction with T cells (Supplementary Figure 5a-c).

254 Enrichment analysis of pathways related to IGF1<sup>+</sup> M $\phi$  and IL1B-CD14 cells revealed  
255 involvement in senescent and inflammatory pathways, including ERK, MAPK and IL-1  
256 pathways. Consequently, IGF1<sup>+</sup> M $\phi$  in the TIME may induce immunosenescence in T cells.  
257 Analysis of TCGA data for HNSCC patients demonstrated that those with high IGF1 signature  
258 had relatively poor OS and progression-free survival (PFS) (Extended Data Fig. 7i and  
259 Supplementary Figure 5d, e). In conclusion, our analysis of myeloid cell subtypes suggests that  
260 IGF1<sup>+</sup> M $\phi$  could be a crucial factor contributing to the limited response of tumor patients to  
261 immunotherapy. These cells may trigger an immunosenescent status in the TIME through their  
262 interactions with T cells.

### 263 **Senolytics combined $\alpha$ PD-1 alleviate TIME senescent burden in HNSCC**

264 Currently, the role of the senescent phenotype in HNSCC and its interaction with tumor  
265 cells, immune cells, or other cell types remains poorly understood. The impact of senolytics  
266 treatments or their combination with other therapies in HNSCC is yet to be determined.  
267 Histochemical staining with  $\beta$ -galactosidase revealed a significantly more pronounced senescent  
268 phenotype in HNSCC tissue compared to the adjacent normal tissue (Fig. 3a). Then, we  
269 established a 4-NQO-induced (4-Nitroquinoline-N-oxide) HNSCC mouse model using 12-  
270 month-old C57BL/6 (C57) mice (Fig. 3b). The mice underwent the typical progression of normal  
271 epithelium-epithelial dysplasia-invasive cancer, with an average age of tumor occurrence around  
272 20 months, reflecting the real progression of HNSCC in elderly patients more accurately  
273 (Extended Data Fig. 8a). Immunofluorescence staining on tumor sections confirmed significantly  
274 higher expression of the key senescent marker P16 in the tumor region compared to surrounding  
275 normal tissue (Fig. 3c).

276 To further investigate the effect of senolytics on HNSCC, we randomly divided the 4-NQO-  
277 induced tumor mice into four groups, administering Isotype,  $\alpha$ PD-1 (anti PD-1),  $\alpha$ PD-1+CP (anti  
278 PD-1+Cisplatin), or  $\alpha$ PD-1+DQ (anti PD-1+Dasatinib+Quercetin) treatments (Fig. 3b). The  
279  $\alpha$ PD-1+DQ group exhibited fewer lesions compared to other groups. Interestingly, there was no  
280 significant difference between the  $\alpha$ PD-1 group and the  $\alpha$ PD-1+CP group (Fig. 3d and Extended  
281 Data Fig. 8b) while  $\alpha$ PD-1+DQ group had a longer lifespan compared to other groups (Fig. 3e  
282 and Extended Data Fig. 8c). Moreover, flow cytometry revealed that  $\alpha$ PD-1+DQ treatment  
283 effectively decreased  $\beta$ -galactosidase expression in CD45<sup>+</sup> immune cells within tumors (Fig. 3f).  
284 Correlation analysis further demonstrated a negative relationship between mice survival time and  
285  $\beta$ -galactosidase expression in immune cells, confirming the anti-tumor effect of  $\alpha$ PD-1+DQ by  
286 reversing immunosenescence in HNSCC mice (Fig. 3g).

287 Subsequently, we evaluated changes in CD4<sup>+</sup>, CD8<sup>+</sup>, and B220<sup>+</sup> cells in the spleen, blood,  
288 bone marrow, and tumors across different treatment groups using flow cytometry. The  $\alpha$ PD-  
289 1+DQ group showed an increased proportion of CD4<sup>+</sup> cells within tumors, while CD8<sup>+</sup> and  
290 B220<sup>+</sup> cell levels exhibited no significant differences compared to other groups (Fig. 3h). Similar  
291 results were observed in the spleen (Extended Data Fig. 8d, e). However, B220<sup>+</sup> cell counts were  
292 relatively elevated in peripheral blood samples from the  $\alpha$ PD-1+DQ group (Extended Data Fig.  
293 8f-g). Additionally, the expression levels of *p16* and *p21* were significantly reduced in tumor-  
294 infiltrating CD4<sup>+</sup> cells from the  $\alpha$ PD-1+DQ group (Fig. 3i), whereas no significant differences  
295 were noted in CD8<sup>+</sup> cells (Extended Data Fig. 8h). Furthermore, an increased proportion of  
296 CD62L<sup>+</sup>CD44<sup>-</sup> naïve CD4<sup>+</sup> cells was observed in the  $\alpha$ PD-1+DQ group (Fig. 3j).  
297 Immunofluorescence staining consistently confirmed a significant increase in CD4<sup>+</sup>CD62L<sup>+</sup> cells  
298 in the  $\alpha$ PD-1+DQ group relative to the other groups (Fig. 3k and Supplementary Figure 6).  
299 Together, these findings suggest that immunosenescence in HNSCC surpasses that in

300 surrounding normal tissue, and the combination of  $\alpha$ PD-1+DQ may enhance the therapeutic  
301 efficacy of  $\alpha$ PD-1 by mitigating the senescent phenotype of tumor immune cells, particularly in  
302 CD4<sup>+</sup> cells.

303 **Synergistic reduction of SASP and increase in CD4<sup>+</sup> Naïve T cells by senolytics and  $\alpha$ PD-1**  
304 **in solid tumors**

305 To determine the effectiveness of  $\alpha$ PD-1+DQ in various transplant tumor models, including  
306 HNSCC, we established two mouse oral squamous cell carcinoma cell lines, 4N-MS1 and 4N-  
307 MS2, from the 4-NQO model (Fig. 4a, Extended Data Fig. 9a, b). To simulate the systemic  
308 senescence in normal elderly mice, we used *Ercc1*<sup>+/-</sup> mice, which exhibit rapid senescent  
309 characteristics such as hair loss and graying like 20-month-old wild-type mice by the age of 10  
310 months (Fig. 4b). Further measurements of spleen weight and 8-hydroxy-2-deoxyguanosine (8-  
311 OHdG) content in the spleen showed that *Ercc1*<sup>+/-</sup> 10m mice had similar 8-OHdG levels and  
312 spleen weight as WT 20m mice. Immunofluorescence staining revealed that 10-month-old  
313 *Ercc1*<sup>+/-</sup> mice expressed more  $\gamma$ H2AX in the spleen, heart, liver, and lungs compared to wild-  
314 type mice (Fig. 4c-e). In summary, *Ercc1*<sup>+/-</sup> 10m mice exhibited senescent characteristics like  
315 naturally aging wild-type mice.

316 We implanted 4N-MS1 cells into the tongues of 10-month-old *Ercc1*<sup>+/-</sup> mice and, on the 5th  
317 day, treated the mice with Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP, or  $\alpha$ PD-1+DQ (Fig. 4f). Tumor growth  
318 curves showed that mice in the  $\alpha$ PD-1+DQ group had better treatment outcomes than other  
319 groups (Fig. 4g). Additionally, we employed the Multiplex bead-based protein analysis method  
320 to measure the expression of various SASP factors in tumor tissue lysates. The results revealed  
321 that  $\alpha$ PD-1+DQ treatment significantly reduced the expression of various SASP factors within  
322 the tumor, including IL-2, TNF- $\alpha$ , IFN- $\gamma$ , IL-10, CCL20, MCP-3, and others (Fig. 4h and

323 Supplementary Table 7). Furthermore, flow cytometric analysis showed an increase in  
324 CD62L<sup>+</sup>CD44<sup>-</sup>CD4<sup>+</sup> Naïve cells in the αPD-1+DQ group compared to the Isotype group (Fig. 4i).  
325 Consistently, immunofluorescence staining confirmed a significant decrease of P21<sup>+</sup> cells in the  
326 αPD-1+DQ group compared to the other three groups (Fig. 4j). Moreover, we implanted MB49  
327 (bladder cancer) and E0771 (breast cancer) tumors subcutaneously in 10-month-old *Ercc1*<sup>+/-</sup>  
328 mice and observed therapeutic outcomes like those seen with the 4N-MS1 transplant model. (Fig.  
329 4k and Extended Data Fig. 9c-f). In summary, these data suggest that αPD-1+DQ treatment can  
330 suppress tumor growth in multiple solid tumors while enhancing immune microenvironment  
331 vitality through reduced SASP and increased CD4<sup>+</sup> Naïve cells.

### 332 **Senolytics reduce senescent characteristics and enhance activation of tumor-infiltrating** 333 **CD4<sup>+</sup> Naïve T cells**

334 To investigate the unique functionality of significantly increased CD4<sup>+</sup>CD62L<sup>+</sup> Naïve T  
335 cells in tumors after combined αPD-1+DQ therapy in anti-tumor immunity, we isolated  
336 CD62L<sup>+</sup>CD44<sup>-</sup>CD4<sup>+</sup> cells from tumors of mice treated with Isotype, αPD-1, or αPD-1+DQ, and  
337 performed RNA-Seq and ATAC-Seq (Fig. 5a). The results of RNA-Seq showed that, compared  
338 to Isotype or αPD-1 treatment, the αPD-1+DQ group exhibited significantly higher expression of  
339 genes related to T-cell migration (*Ccr7*) or antigen response (*Lck*, *Cfd*) in Naïve T cells (Fig. 5b,  
340 Extended Data Fig. 10a and Supplementary Table 8). GO analysis revealed enrichment in  
341 pathways related to T-cell maintenance, differentiation, and antigen presentation for both αPD-  
342 1+DQ and Isotype groups, indicating that the combination of senolytics with αPD-1 may  
343 enhance immune response levels by promoting proliferation and differentiation of Naïve T cells  
344 (Fig. 5c and Extended Data Fig. 10b). Additionally, ATAC-Seq analysis demonstrated that,  
345 relative to Isotype or αPD-1 treatment, the αPD-1+DQ group exhibited significantly higher  
346 chromatin accessibility of the *Ccr7* gene, crucial for adaptive immune responses. Conversely,

347 genes associated with immunosenescence and chronic inflammation, such as *S100a11*, showed  
348 lower chromatin accessibility (Fig. 5d, Extended Data Fig. 10c-g and Supplementary Table 9).  
349 Furthermore, joint GO analysis of RNA-Seq and ATAC-Seq results from the  $\alpha$ PD-1+DQ and  
350 Isotype groups yielded similar findings (Fig. 5e). qPCR measurements confirmed that  $\alpha$ PD-  
351 1+DQ treatment upregulated genes associated with T cell activation, such as *Ccr7*, *Lck*, and *Cfd*,  
352 and downregulated genes linked to immunosenescence, including *p16*, *p21*, and *S100a11*, in  
353 tumor-infiltrating CD4<sup>+</sup> Naïve T cells. (Fig. 5f). Additionally, flow cytometry and  
354 immunofluorescence staining also demonstrated a significant increase in CCR7 and LCK-  
355 positive CD4<sup>+</sup> Naïve T cells following  $\alpha$ PD-1+DQ treatment (Fig. 5g, h). In conclusion, our  
356 results indicate that  $\alpha$ PD-1+DQ treatment effectively reduces the senescent phenotype while  
357 markedly enhancing the quantity and differentiation potential of tumor-infiltrating CD4<sup>+</sup> Naïve T  
358 cells.

### 359 **Combination of anti-PD-1 with Dasatinib and Quercetin Demonstrates Safety and Efficacy** 360 **in Patients with HNSCC.**

361 Previous studies have indicated that neoadjuvant chemotherapy reduces recurrence in  
362 patients with locally advanced oral cancer but does not improve survival rates<sup>27,28</sup>. Recent  
363 research indicates that chemotherapy can exacerbate the adverse effects associated with  
364 immunotherapy. The most prevalent adverse effects of neoadjuvant immunochemotherapy  
365 include alopecia (100.0%), nausea/vomiting (60.4%), and fatigue (50.0%)<sup>29</sup>. Therefore, it is  
366 essential to investigate novel therapeutic agents that can enhance the efficacy of immunotherapy  
367 while minimizing systemic side effects, preserving the function of vital organs, and ultimately  
368 improving the quality of life for patients.



369           Based on our findings from single-cell multi-omics analysis and animal models, we  
370 hypothesized that combining ICIs with dasatinib and quercetin would be both effective and safe  
371 for patients with HNSCC, significantly reducing TRAEs compared to standard neoadjuvant  
372 chemotherapy. To evaluate this hypothesis, we conducted a prospective, open-label, single-  
373 center, Phase II clinical trial (COIS-01), assessing the neoadjuvant efficacy of tislelizumab  
374 combined with dasatinib and quercetin in resectable HNSCC patients. The primary endpoint of  
375 the study was the MPR rate (Fig. 6a). Between February 5, 2023, and April 5, 2024, a total of 24  
376 patients were enrolled according to the study protocol. Efficacy evaluations revealed that 4  
377 patients (16.7%) achieved a pCR, while another 4 (16.7%) achieved a MPR, resulting in an  
378 overall treatment response rate of 33.3% (pCR + MPR) (Fig. 6b and Supplementary Table 10).  
379 Representative imaging, pathological assessments, and clinical photographs of patients achieving  
380 pCR are provided (Fig. 6c).

381           Safety analyses of the 24 patients demonstrated that only 1 patient experienced grade 3-4  
382 TRAEs (Fig. 6d). In contrast, the OOC-001 trial, which evaluated neoadjuvant chemotherapy,  
383 showed the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea  
384 (49%) (Fig. 6e, Supplementary Table 2). In the COIS-01 trial, the corresponding incidences were  
385 notably lower, with 0% for alopecia, 25% for asthenia or fatigue, and 16.7% for nausea  
386 (Supplementary Table 11). Although the survival period in COIS-01 has not yet allowed for  
387 statistical analysis of overall survival, no recurrences or deaths have been observed to date.  
388 Furthermore, immunohistochemical analysis of patient paraffin sections before and after  $\alpha$ PD-1  
389 + DQ treatment revealed an upregulation of CCR7 expression in naïve T cells post-treatment  
390 (Fig. 6f). These early findings from the COIS-01 trial suggest that the combination of  
391 tislelizumab with dasatinib and quercetin demonstrates promising antitumor efficacy, favorable  
392 tolerability, and a potential to mitigate immunosenescence-related features.

393

## 394 **Discussion**

395 The central conclusion of this study is that the senescence of TIME is a critical factor  
396 affecting the efficacy of tumor immunotherapy. The first evidence supporting this conclusion  
397 comes from the multidimensional single-cell data analysis of immune cells from both blood and  
398 tumors of patients in clinical trials. We observed that noMPR patients exhibited more  
399 pronounced immunosenescence features, including a decreased proportion of naïve T cells and  
400 memory B cells, an increased proportion of immunosuppressive cell subtypes, and a reduction in  
401 the TCR/BCR repertoire. Additionally, we identified IAGs in immune cells from noMPR  
402 patients, which showed higher expression levels across various T and B cell subsets. When  
403 tumor-bearing mice received a combination of ICI and senolytics, we observed an increase in  
404 CD4<sup>+</sup> naïve T cells and a reduction in senescence markers in immune cells within the tumors.  
405 This led to reduced tumor burden and extended survival in the mice. A clinical trial based on our  
406 findings further confirmed the potential advantage of combining ICI with senolytics for treating  
407 solid tumors.

408 Immune cells are the cornerstone of tumor immunotherapy<sup>30,31</sup>. T cell-centered therapies  
409 have become powerful tools against cancer. ICI is the most widely used immunotherapy method  
410 for solid malignancies, with an increasing number of monoclonal antibodies targeting different  
411 inhibitory receptors entering clinical practice<sup>32</sup>. Antibodies against PD-1, CTLA-4, and LAG-3  
412 have been FDA-approved for several types of solid tumors. Although ICI can induce objective  
413 responses even in the challenging context of metastatic disease, only a minority of patients  
414 (estimated at <30%) achieve sustained and/or complete clinical responses<sup>33-35</sup>. The TIME is rich  
415 in tumor-reactive T cells, but exhaustion remains a major factor limiting their antitumor

416 capabilities. Studies on chronic antigen stimulation models in mice<sup>36–38</sup> and the characteristics of  
417 tumor-infiltrating lymphocytes (TILs) in human "hot" tumors<sup>39–41</sup> emphasize that antitumor T  
418 cells can progressively acquire a dysfunctional state, allowing tumor immune evasion<sup>42,43</sup>. These  
419 findings suggest that the TIME is not isolated but interconnected with the systemic immune  
420 system. The dynamic processes of TILs dysfunction and continuous recruitment of immune cells  
421 to the tumor provide a new perspective for exploring ways to improve the TIME during tumor  
422 progression.

423 Notably, our study shows no significant differences in the proportions of most immune cell  
424 types in the peripheral blood of responsive and non-responsive patients before and after  
425 treatment. This indicates that predicting immunotherapy responses based on peripheral blood  
426 tests may be challenging. Although cellular senescence drives various age-related complications  
427 through SASP, identifying senescent immune cells in vivo remains difficult<sup>44–46</sup>. Recent studies  
428 have identified a set of genes (SenMayo) enriched in bone biopsies from elderly individuals,  
429 capable of identifying senescent hematopoietic or stromal cells at the single-cell level in human  
430 and mouse bone marrow/bone scRNA-Seq data<sup>46</sup>. Researchers also established AgeAnno, a  
431 human aging single-cell annotation knowledge base, offering dynamic functional annotations of  
432 1,678,610 cells from 28 healthy tissue samples<sup>47</sup>. Currently, there are no specific markers or  
433 gene sets dedicated to reflecting the degree of immunosenescence. We have constructed an  
434 immunosenescence-related gene set comprising 154 genes (IAGs), which has effectively  
435 distinguished between young and elderly individuals in external datasets. This provides a  
436 powerful tool for future research on the senescent status of the immune system. It is important to  
437 note that the immune system consists of diverse cell types, each with distinct functions. For  
438 example, the gene expression profiles of senescent states in T cells, dendritic cells, and

439 macrophages may differ significantly. Understanding these differences is crucial for developing  
440 targeted therapies for senescent phenotypes.

441 Senolytics therapies for various cancers are currently under investigation. Studies have  
442 shown that senolytics ABT-263 can exert antitumor effects by selectively clearing senescent  
443 cells in obese patients' tumor tissues<sup>48</sup>. Additionally, the plant compound Rutin, when combined  
444 with chemotherapy, can intervene in tumor development<sup>49</sup>. These studies suggest that senolytics  
445 may offer unique advantages in cancer treatment, with fewer side effects and promoting overall  
446 systemic health. However, the combination of senolytics and ICI has not been explored in TIME.  
447 Previous research discussed the potential benefits of DQ therapy, a novel senolytics regimen that  
448 disrupts survival pathways of senescent cells and selectively targets them<sup>50-52</sup>. Recent research  
449 on systemic administration of DQ for treating intervertebral disc degeneration has provided new  
450 insights, highlighting the tissue-specific effects of DQ and the importance of treatment timing<sup>53</sup>.  
451 Additionally, a clinical trial on DQ treatment for idiopathic pulmonary fibrosis (IPF)  
452 demonstrated significant improvements in patients' physical function<sup>54,55</sup>. Our COIS-01 trial has  
453 demonstrated the efficacy and safety of combining senolytics with ICIs in HNSCC patients.  
454 Previous studies have shown that ICIs monotherapy in HNSCC has limited effectiveness, with  
455 reported MPR rates of 7-13.9%<sup>56-58</sup>. In contrast, the COIS-01 trial achieved an MPR rate of  
456 33.3%. While immunochemotherapy can achieve higher MPR rates, it is associated with  
457 significant toxicity, with grade  $\geq 3$  adverse events occurring in up to 35% of patients<sup>59</sup>,  
458 substantially higher than in the COIS-01 trial, where the incidence of such events was  
459 considerably lower (4.2%). Grade  $\geq 3$  toxicities can severely impact patient quality of life and  
460 pose challenges for subsequent adjuvant immunotherapy. Discontinuation of adjuvant

461 immunotherapy due to toxicity may compromise the overall therapeutic efficacy, potentially  
462 affecting survival outcomes<sup>60</sup>.

463         Given this balance between efficacy and risk, the COIS-01 trial offers a novel therapeutic  
464 strategy that maximizes the antitumor efficacy of ICIs while minimizing adverse events.  
465 Preclinical studies in multiple mouse models have demonstrated the superior potential for long-  
466 term survival with the combination of  $\alpha$ PD-1 and senolytics (dasatinib and quercetin) compared  
467 to monoimmunotherapy or immunochemotherapy. Consistently, the combination of senolytics  
468 and anti-PD-1 therapy has been shown to dramatically upregulate CCR7<sup>+</sup> naïve T cells in COIS-  
469 01 patients, a critical feature in the modulation of immunosenescence<sup>61</sup>. This upregulation  
470 enhances the homing<sup>62</sup>, immune surveillance<sup>63</sup>, and circulating maintenance<sup>64</sup> of these specific  
471 T cells, potentially predicting improved survival outcomes in clinical settings. However, rigorous  
472 randomized clinical trials are needed to further validate these findings. Additionally, further  
473 investigation is required to determine the optimal type and dosage of senolytics in combination  
474 with ICIs.

475         In summary, this study provides valuable insights into the variability of the tumor immune  
476 microenvironment (TIME) across individuals and highlights the potential for enhancing  
477 antitumor efficacy by targeting immunosenescence within the TIME. These findings offer a  
478 promising avenue for improving outcomes in patients with HNSCC.

479

## 480 **References**

- 481 1. Cramer, J. D., Burtneß, B. & Ferris, R. L. Immunotherapy for head and neck cancer: Recent advances and  
482 future directions. *Oral Oncology* **99**, 104460 (2019).
- 483 2. Bernier, J. *et al.* Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced  
484 Head and Neck Cancer. *The New England Journal of Medicine* (2004).

- 485 3. Cooper, J. S. *et al.* Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell  
486 Carcinoma of the Head and Neck. *N Engl J Med* **350**, 1937–1944 (2004).
- 487 4. Puram, S. V. *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head  
488 and Neck Cancer. *Cell* **171**, 1611-1624.e24 (2017).
- 489 5. Li, J. *et al.* Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-  
490 deficient colorectal cancer. *Cancer Cell* **41**, 1152-1169.e7 (2023).
- 491 6. Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. *Nat Rev Cancer* **23**,  
492 295–316 (2023).
- 493 7. Bhatia, A. & Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive  
494 review. *Expert Review of Clinical Immunology* **10**, 41–62 (2014).
- 495 8. Tumei, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**,  
496 568–571 (2014).
- 497 9. Galon, J. *et al.* Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. *The*  
498 *Journal of Pathology* **232**, 199–209 (2014).
- 499 10. Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact  
500 on clinical outcome. *Nat Rev Cancer* **12**, 298–306 (2012).
- 501 11. Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of solid organs. *Nature* **594**,  
502 100–105 (2021).
- 503 12. Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. *Nat*  
504 *Immunol* **14**, 428–436 (2013).
- 505 13. Liu, Z. *et al.* Immunosenescence: molecular mechanisms and diseases. *Sig Transduct Target Ther* **8**, 200  
506 (2023).
- 507 14. Zinatizadeh, M. R. *et al.* Immunosenescence and inflamm-ageing in COVID-19. *Ageing Research Reviews* **84**,  
508 101818 (2023).
- 509 15. Ferrara, R. *et al.* Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer  
510 Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clinical Cancer Research*  
511 **27**, 492–503 (2021).
- 512 16. Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. *J Hematol*  
513 *Oncol* **13**, 151 (2020).

- 514 17. Liu, X. *et al.* Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor  
515 immunity and immunotherapy. *J Immunother Cancer* **10**, e005020 (2022).
- 516 18. Park, M. D. *et al.* Hematopoietic aging promotes cancer by fueling IL-1 $\beta$ -driven emergency myelopoiesis.  
517 *Science* eadn0327 (2024) doi:10.1126/science.adn0327.
- 518 19. Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P. & Brondello, J.-M. Cellular senescence  
519 impact on immune cell fate and function. *Aging Cell* **15**, 400–406 (2016).
- 520 20. Pinti, M. *et al.* Aging of the immune system – focus on inflammation and vaccination. (2017).
- 521 21. Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. *Nat Immunol* **22**, 687–698 (2021).
- 522 22. López-Otín, C. Hallmarks of aging: An expanding universe.
- 523 23. Swanton, C. *et al.* Embracing cancer complexity: Hallmarks of systemic disease. *Cell* **187**, 1589–1616 (2024).
- 524 24. Luo, O. J. *et al.* Multidimensional single-cell analysis of human peripheral blood reveals characteristic features  
525 of the immune system landscape in aging and frailty. *Nat Aging* **2**, 348–364 (2022).
- 526 25. Weivoda, M. M. *et al.* Identification of osteoclast-osteoblast coupling factors in humans reveals links between  
527 bone and energy metabolism. *Nat Commun* **11**, 87 (2020).
- 528 26. Zhang, Y. *et al.* Single-cell analyses reveal key immune cell subsets associated with response to PD-L1  
529 blockade in triple-negative breast cancer. *Cancer Cell* **39**, 1578-1593.e8 (2021).
- 530 27. Marta, G. N. *et al.* Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral  
531 cavity cancer patients: Systematic review and meta-analysis. *Eur J Cancer* **51**, 2596–2603 (2015).
- 532 28. Liu, J. *et al.* Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic  
533 Disease. *Cancer Discov* **6**, 1382–1399 (2016).
- 534 29. D, W. *et al.* Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in  
535 resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. *Nature*  
536 *communications* **15**, (2024).
- 537 30. Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. *Nat Rev Immunol* **20**,  
538 75–76 (2020).
- 539 31. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell  
540 response. *Nat Rev Immunol* **12**, 269–281 (2012).
- 541 32. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).

- 542 33. Bagchi, S., Yuan, R. & Engleman, E. G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical  
543 Impact and Mechanisms of Response and Resistance. *Annu. Rev. Pathol. Mech. Dis.* **16**, 223–249 (2021).
- 544 34. Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to  
545 immune checkpoint blockade. *Cell* **184**, 5309–5337 (2021).
- 546 35. De Miguel, M. & Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. *Cancer Cell* **38**, 326–333  
547 (2020).
- 548 36. Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* **537**, 417–  
549 421 (2016).
- 550 37. Siddiqui, I. *et al.* Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in  
551 Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* **50**, 195–211.e10 (2019).
- 552 38. Utzschneider, D. T. *et al.* T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune  
553 Response to Chronic Viral Infections. *Immunity* **45**, 415–427 (2016).
- 554 39. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in  
555 Melanoma. *Cell* **175**, 998–1013.e20 (2018).
- 556 40. Li, H. *et al.* Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within  
557 Human Melanoma. *Cell* **176**, 775–789.e18 (2019).
- 558 41. Van Der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights  
559 from single-cell analysis. *Nat Rev Cancer* **20**, 218–232 (2020).
- 560 42. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. *Cancer Cell* **33**, 547–562 (2018).
- 561 43. Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* **22**, 209–  
562 223 (2022).
- 563 44. Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* **530**, 184–189  
564 (2016).
- 565 45. Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat Med* **24**, 1246–1256  
566 (2018).
- 567 46. Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-associated pathways across  
568 tissues. *Nat Commun* **13**, 4827 (2022).
- 569 47. Huang, K. *et al.* AgeAnno: a knowledgebase of single-cell annotation of aging in human. *Nucleic Acids*  
570 *Research* **51**, D805–D815 (2023).



- 571 48. Chang, J. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat*  
572 *Med* **22**, 78–83 (2016).
- 573 49. Liu, H. *et al.* Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic  
574 efficacy. *Aging Cell* **23**, e13921 (2024).
- 575 50. Schafer, M. J. *et al.* Cellular senescence mediates fibrotic pulmonary disease. *Nat Commun* **8**, 14532 (2017).
- 576 51. Farr, J. N. *et al.* Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med* **23**, 1072–1079  
577 (2017).
- 578 52. Zhang, P. *et al.* Senolytic therapy alleviates A $\beta$ -associated oligodendrocyte progenitor cell senescence and  
579 cognitive deficits in an Alzheimer’s disease model. *Nat Neurosci* **22**, 719–728 (2019).
- 580 53. Novais, E. J. *et al.* Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-  
581 dependent intervertebral disc degeneration in mice. *Nat Commun* **12**, 5213 (2021).
- 582 54. Hickson, L. J. *et al.* Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of  
583 Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456 (2019).
- 584 55. Justice, J. N. *et al.* Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot  
585 study. *EBioMedicine* **40**, 554–563 (2019).
- 586 56. Jd, S. *et al.* Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell  
587 Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. *JAMA oncology* **6**, (2020).
- 588 57. R, U. *et al.* Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human  
589 Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clinical cancer research*: an  
590 official journal of the American Association for Cancer Research **26**, (2020).
- 591 58. Wise-Draper, T. M. *et al.* Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable  
592 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res* **28**, 1345–1352  
593 (2022).
- 594 59. Zinner, R. *et al.* 968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in  
595 HPV(-) resectable locally advanced head and neck cancer. *Annals of Oncology* **31**, S682 (2020).
- 596 60. Ce, H. *et al.* Adjuvant immunotherapy: the sting in the tail. *European journal of cancer (Oxford, England*:  
597 *1990)* **132**, (2020).

- 598 61. Soto-Herederó, G., Gómez de Las Heras, M. M., Escrig-Larena, J. I. & Mittelbrunn, M. Extremely  
599 Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging. *Annu Rev Immunol* **41**, 181–  
600 205 (2023).
- 601 62. Cao, W. *et al.* TRIB2 safeguards naive T cell homeostasis during aging. *Cell Rep* **42**, 112195 (2023).
- 602 63. Sharma, S. *et al.* Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells:  
603 implications for T-cell immunotherapy. *J Immunother Cancer* **11**, e006267 (2023).
- 604 64. Czystowska, M. *et al.* The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates  
605 with disease recurrence in patients with HNSCC. *Clin Cancer Res* **19**, 889–899 (2013).
- 606
- 607

## 608 **Methods:**

609

### 610 **Human specimens**

611 This study includes three independent clinical trials for HNSCC: OOC-001 (NCT04718415),  
612 REDUCTION-I (NCT05582265), and COIS-01 (NCT05724329). Eligible HNSCC patients  
613 received prior approval from the Institutional Review Board (IRB) at Sun Yat-sen Memorial  
614 Hospital, Sun Yat-sen University, and were required to provide written informed consent to  
615 participate in the study. All patients were diagnosed with HNSCC by expert histopathologists,  
616 and all invasive procedures and systemic treatments were ordered by the patients' attending  
617 physicians, individually determined based on the response after the administration of  
618 pharmacological drugs. The eight patients used for the scRNA-Seq study were part of the OOC-  
619 001 clinical trial and received the described treatment regimen. Specifically, all patients had their  
620 primary tumor tissue and peripheral blood collected through biopsy at the time of enrollment,  
621 and the peripheral blood was collected after sintilimab in combination with carboplatin and nab-  
622 paclitaxel treatment before surgery. Among the 7 patients (SH1-SH7) who underwent surgery, 3

623 patients are MPR, and 4 patients are noMPR. Paired biopsy samples of primary tumor tissue and  
624 peripheral blood were collected at baseline before treatment, and peripheral blood samples were  
625 collected 3 weeks after the first dosing cycle. Except for SH1, peripheral blood samples were  
626 collected from the other patients before and after the first medication cycle for matching. For  
627 patient SH1, blood samples were collected only before the first medication cycle. Peripheral  
628 blood samples were collected after the second medication cycle for SH1, SH2, SH3, and SH4,  
629 and peripheral blood samples were collected for SH3, SH4, and SH7 after the third medication  
630 cycle. Paraffin sections from two ongoing clinical study patient cohorts were used for  
631 immunofluorescence staining of senescent markers P16 and P21. This included 33 MPR patients  
632 and 17 noMPR patients from OOC-001, as well as 37 MPR patients and 24 noMPR patients  
633 from REDUCTION-I. Another set from COIS-01 collected paraffin sections from 7 patients for  
634 immunofluorescence staining before and after treatment.

### 635 **Sample collection and processing**

636 Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufacturer's  
637 protocol. Briefly, before the start of treatment, 5 mL of fresh peripheral blood was collected in  
638 EDTA anticoagulated tubes and subsequently extracted with Lymphoprep™ (Stem Cells)  
639 solution. After centrifugation, carefully transfer lymphocytes to a new 50 mL tube and wash with  
640 PBS. Next, incubate the lymphocytes for 10 minutes to lyse the blood cells. Finally, cells were  
641 resuspended in sorting buffer containing PBS plus 2% FBS.

642 For tumor biopsy samples, cut tissue with a diameter of about 5 mm at the junction of the  
643 tumor and normal tissue as a representative sample. All 7 tumor biopsy samples were collected  
644 as a discovery cohort through routine clinical practice and then stored in MACS Tissue Storage  
645 Solution (Miltenyi). Fresh biopsy samples of oral HNSCC were minced and isolated using a  
646 human tumor isolation kit (Miltenyi), followed by enzymatic digestion on a rotor at 37°C for 45–

647 60 min. The detached cells were then passed through 70  $\mu\text{m}$  and 40  $\mu\text{m}$  cell filters (Biosharp)  
648 and centrifuged at  $300 \times g$  for 10 min. Pelleted cells were suspended in red blood cell lysis buffer  
649 (Thermo-Fisher) and incubated on ice for 2 min, then washed and resuspended in phosphate  
650 buffer supplemented with 2% fetal bovine serum (FBS, ExCell) PBS twice in saline (PBS,  
651 Gibco). The viability of all samples was confirmed to be  $>90\%$  using the trypan blue (Thermo-  
652 Fisher) exclusion method.

### 653 **Single-cell RNA-seq library and TCR-seq library preparation and sequencing**

654 According to the manufacturer's protocol, scRNA-seq libraries were constructed. In  
655 summary, the density of cells was determined after washing once with PBS containing 0.04%  
656 bovine serum albumin (BSA, Invitrogen). Next,  $2 \times 10^5$  cells were loaded on a 10x Genomics  
657 GemCode Single cell instrument (10x Genomics) that generates single-cell Gel Bead-In-  
658 EMulsion (GEMs). Libraries were generated and sequenced from the cDNAs with the  
659 Chromium Next GEM Automated Single Cell 3' cDNA Kitv3.1 (10x Genomics). Upon  
660 dissolution of the Gel Bead in a GEM, primers were released and mixed with cell lysate and  
661 Master Mix. Barcoded, full length cDNAs were then reverse-transcribed from polyadenylated  
662 mRNA. Full-length, barcoded cDNAs were then amplified by quantitative real-time PCR  
663 (qRT-PCR) for library construction. Finally, single-cell RNA libraries were sequenced by an  
664 Illumina HiSeq X Ten sequencer with 150 bp paired-end reads.

665 After reverse transcription and cell barcoding, the cDNA was de-emulsified and purified  
666 using silane magnetic beads, followed by PCR amplification. The amplified cDNA was then  
667 used for 5' gene expression library construction and TCR V(D)J targeted enrichment  
668 amplification using the Illumina® bridge. Libraries prepared according to the manufacturer's  
669 user guide were then purified and analyzed for quality assessment. Single-cell RNA and TCR

670 V(D)J libraries were sequenced by an Illumina HiSeq X Ten sequencer using 150 bp paired-end  
671 reads.

### 672 **Bulk TCR-seq library preparation and sequencing**

673 Whole Blood Samples Blood was collected in EDTA tubes and sent to isolated PBMCs, and  
674 DNA was extracted for TCR $\beta$  analysis by immunoSEQ<sup>65</sup>. Briefly, extracted genomic DNA was  
675 amplified using a bias-controlled multiplex PCR system, followed by high-throughput  
676 sequencing. Raw data processing and analysis were performed by immunoSEQ. Subsequently,  
677 we used the International ImMunoGeneTics Information System (IMGT; <http://imgt.cines.fr>)  
678 database for comparison. After the alignment, the relative abundance of each TCR $\beta$  CDR3  
679 sequence was clarified and calculated. Furthermore, we use batch correction to eliminate batch  
680 effects across different datasets. Subsequently, multiple TCR data statistics were performed.

### 681 **Bulk ATAC and RNA isolation and sequencing**

682 Isolation, library construction and sequencing of bulk ATAC and RNA were performed at  
683 Gene Denovo Biotechnology Co. (Guangzhou, China). For ATAC sequencing, CD4 naïve cells  
684 from C57 mouse tongue tumors were extracted. Tn5 transposase was added to the nuclear  
685 suspension. After the reaction was completed, the DNA fragment was purified; the amplified  
686 product was then used for PCR amplification. The fragments were purified using AMPure XP  
687 magnetic beads (Beckman Coulter, Brea, CA, USA) to construct a sequencing library. After the  
688 library construction was completed, Agilent 2100 (Agilent, Santa Clara, CA) was used to detect  
689 the quality of the library. Libraries that pass the quality inspection will be used for on-machine  
690 sequencing (Novaseq 6000) to obtain sequence information of the open chromatin region  
691 fragments to be tested.

692 Extraction of CD4 naïve cells from C57 mouse tongue tumors. Total RNA was extracted  
693 using Trizol reagent kit (Invitrogen) according to the manufacturer's protocol. RNA quality was

694 assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies). After total RNA was extracted,  
695 eukaryotic mRNA was enriched by Oligo(dT) beads. Then the enriched mRNA was reversely  
696 transcribed into cDNA by using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB #7530,  
697 New England Biolabs). The resulting cDNA library was sequenced using Illumina Novaseq6000  
698 by Gene Denovo Biotechnology Co. (Guangzhou, China).

### 699 **scRNA-Seq data processing**

700 The Cell Ranger toolkit (version 3.1.0) provided by 10x Genomics was applied to aggregate  
701 raw data, filter low-quality reads, align reads to the human reference genome (GRCh38), assign  
702 cell barcodes and generate a UMI matrix. The toolkit Scanpy (version 1.9.3)<sup>66</sup> was used to  
703 analyze single-cell RNA sequencing (scRNA-Seq) data. Specifically, the original UMI matrix  
704 was processed to filter out genes expressed in less than 10 cells and cells with less than 200  
705 genes. We further quantified the number of genes and UMI counts per cell and maintained  
706 thresholds for high-quality cells of 1000-50,000 UMIs, 400-6,000 genes and less than 10%  
707 mitochondrial gene counts, ensuring that most heterogeneous cell types were incorporate into  
708 downstream analyses. Scrublet (version 0.2.3)<sup>67</sup> was then applied to each sequencing library to  
709 remove potential doublets, using default parameters. The normalized expression matrix was  
710 calculated from raw UMI counts normalized to total counts per cell (library size) and then scaled  
711 by 1e4 and log-transformed.

### 712 **Dimensionality reduction and unsupervised clustering of scRNA-seq data**

713 Dimensionality reduction and unsupervised clustering were performed according to  
714 standard workflows in Scanpy<sup>66</sup>. Briefly, use highly variable genes (HVG) based on the  
715 highly\_variable\_genes default parameters. Unwanted sources of variation, including total counts,  
716 and mitochondrial gene counts were further regressed from the normalized expression matrix.  
717 Primary component analysis (PCA) was performed on the variable gene matrix to reduce noise

718 and the top 50 components were used for downstream analysis. To correct for batch effects  
719 across different patients, we applied BBKNN to generate a batch-balanced k-nearest neighbor  
720 (KNN) map, which identifies the top neighbors of each cell in each batch individually, rather  
721 than the entire pool of cells<sup>67</sup>. The Leiden algorithm is then applied to such nearest neighbor  
722 graphs to detect communities and find cell clusters<sup>68</sup>. It is worth noting that the same principal  
723 components are also used for nonlinear dimensionality reduction to generate uniform  
724 distributions for visualization in Uniform Manifold Approximation and Projection (UMAP).  
725 After the first round of unsupervised clustering, we annotated each cell cluster according to  
726 canonical immune cell markers and identified the main immune cell types, including T cells, NK  
727 cells, B cells, myeloid cells, fibroblasts, endothelial cells and tumor cells. Use the  
728 `rank_genes_groups` function with parameter `method Wilcoxon` to detect marker gene.

### 729 **TCR sequences assembly**

730 Applying the TCR sequence assembly Cell Ranger toolkit (version 3.1.0) provided by 10x  
731 Genomics will perform FASTQ sequence quality filtering, sequence alignment, V(D)J assembly  
732 and TCR $\alpha\beta$  pairing. Only TCRs containing paired TRAV-CDR3-TRAJ and TRBV-CDR3-  
733 TRBJ-TRBC chains were considered valid and retained for downstream analysis. Each cell is  
734 assigned a pair of  $\alpha$  and  $\beta$  chains with the highest UMI count. Cells with identical TCR pairs are  
735 defined as clonal and are thought to originate from a common ancestor.

### 736 **Calculation of Diversity Index**

737 Characterize the immune repertoire by examining diversity and clonality. Immune  
738 repertoire analysis involves a variety of diversity indices, such as Chao1 index, Clone Diversity  
739 Index, Richness index and Shannon index<sup>24</sup>.

### 740 **Bulk RNA-sequencing and ATAC-sequencing data processing**

741 For bulk RNA-Seq data, reads were filtered using FASTQ (0.23.3) default parameters, and  
742 then clean reads were aligned to the mouse genome GRCm39 and gencode. vM30 annotations  
743 were using STAR (2.7.10b) and using RSEM (1.3.1) rsem-calculate-expression is in quantitative  
744 analysis of gene expression. Difference analysis was done using DESeq2 (1.42.0).

745 For bulk ATAC data, use FASTQ (0.23.3) for quality control, then use bwa (0.7.17) to align  
746 the reads to the reference genome (GRCm39), and peak using Genrich (0.6.1, [https://github.com](https://github.com/jsh58/Genrich)  
747 [/jsh58/Genrich](https://github.com/jsh58/Genrich)). Peak is annotated to gencode. vM30 through annotatePeaks.pl of HOMER  
748 (4.11). The difference peak is obtained by BEDTools (v2.31.1) subtract.  
749 (<https://github.com/jsh58/ATAC-seq2>)

#### 750 **Generation of Immunosenesence gene set**

751 Our own senescence-related gene set was generated by combining genes reported to be  
752 enriched in senescent immune cells in previous studies and experimentally validated in at least  
753 human or mouse cells. We screened 1745 studies, but after removing studies reporting duplicates,  
754 case reports, non-human genes, and non-high-throughput sequencing, a list of 6 studies was  
755 developed (Senmayo <sup>46</sup>, GSE157007 <sup>24</sup>, HRA000624 <sup>69</sup>, HRA000395 <sup>70</sup>, HRA000615 <sup>71</sup> and  
756 HSA000203 <sup>72</sup> and 1 database (<https://genomics.senescence.info/cells/>)). We screen immune  
757 cells and compare samples from young and old people to obtain differential genes that are highly  
758 expressed in the elderly, remove duplicate genes, and screen genes that appear in at least two  
759 data sets. Based on the enrichment of relevant gene pathways and machines Learning method,  
760 154 genes constituting the immunosenescence gene set were identified (Supplementary Table 6).

#### 761 **GO enrichment analysis and Gene set enrichment analysis (GSEA)**

762 Using the R package ClusterProfiler (version 4.8.3), gene function annotation and GO were  
763 performed on genes that were down-regulated and up-regulated in T cells and B cells in the MPR  
764 and noMPR groups, as well as differential genes between macrophages and monocytes and other



765 cells. Analysis, a program that supports statistical analysis and visualization of functional  
766 profiles of genes and gene clusters.

767 GSEA was performed by the GSEA software  
768 (<http://software.broadinstitute.org/gsea/index.jsp>)<sup>73</sup>. Gene sets used in this article were  
769 c2.cp.kegg.v6.2.symbols.gmt downloaded from the Molecular Signatures Database (MSigDB,  
770 [http:// software.broadinstitute.org/gsea/msigdb/index.jsp](http://software.broadinstitute.org/gsea/msigdb/index.jsp)).

### 771 **Gene Set Score Analysis**

772 The scoregenes function in Scanpy is used to calculate the module score of a gene  
773 expression program in a single cell. First, all analyzed genes were binned according to their  
774 average expression, and control genes were randomly selected from each bin. Then, the average  
775 expression value of the gene set at the single-cell level minus the aggregate expression of the  
776 control gene set was calculated. The gene set was obtained from the immunosenescence gene set  
777 constructed by ourselves. The genes in each gene set are listed in Supplementary Table 6.

### 778 **Cell-cell interaction**

779 We used the CellChat package (1.6.1), which allows analysis of scRNA-Seq data. We  
780 studied the interaction between immune cells (i.e. T cells and B cells) and myeloid cells (i.e.  
781 macrophages and monocytes), one of which contributes ligands or receptors during the  
782 interaction, using CellChat Signaling pathway networks are analyzed and visualized.

### 783 **Trajectory inference of immune cell subsets across tissues**

784 The status of immune cell subpopulations in the periphery and in tumors is dynamic, and  
785 they may differentiate into different cell states and exert different biological functions in  
786 different patients. We use the pseudo-temporal inference algorithm Monocle 2 for trajectory  
787 analysis to reconstruct the cell differentiation trajectory of immune cells across tissues, reveal the

788 progression of cells and reconstruct the trajectory of cells progressing through biological  
789 processes under study.

## 790 **Survival analysis**

791 Survival analysis uses TCGA and HNSCC data to evaluate the prognostic performance of  
792 different immune cell populations. Gene expression data and clinical information of HNSCC  
793 patients were downloaded from cBioPortal (<https://www.cbioportal.org/study/clinicalData>). Use  
794 Cibersort and Xcell to extract T cells and B cells subtypes and group them based on the  
795 expression levels of characteristic genes. Specifically, HNSCC patients were divided into four  
796 groups based on the median proportion of immune cell subsets and the median mean expression  
797 of a given signature gene. In the analysis of myeloid cells, a subset of cells within a single cell is  
798 characterized using a set of signature genes, defined based on a combination of typical marker  
799 genes for major immune cell types and cluster-specific marker genes. Specifically, for different  
800 macrophage clusters, we used the typical IGF1<sup>+</sup> M $\phi$  marker genes "CD276", "APOE", "TREM2",  
801 "HTRA1", "PTGRI", "RBPI", "IGF1", "CDKN1A", "CD81" define its signature. HNSCC  
802 patients were divided into two groups based on the median of the mean expression of the given  
803 signature. Survival analysis was performed using the COX proportional hazards model  
804 implemented in the R package "survival".

## 805 **Hierarchical Clustering**

806 In the end, cell subpopulations and characteristic genes were used to construct a  
807 neoadjuvant treatment model for patients before surgery, and a hierarchical clustering method  
808 was used to create groups. Cophenetic distance was used to evaluate the objects in the group so  
809 that they were like each other and different from objects in other groups. Verify different cell  
810 subpopulations and gene signatures to evaluate the efficacy of neoadjuvant therapy in patients  
811 before surgery.

## 812 **TNBC single cell RNA sequencing data processing**

813 TNBC single-cell RNA sequencing data comes from GSE169246. Patients who received  
814 combined neoadjuvant chemotherapy and immune therapy before surgery were screened, and the  
815 patients were divided into PR (response) and SD (non-response) groups based on the  
816 corresponding imaging conditions. The rest of the analysis process as before, similar cell  
817 subpopulations were evaluated after dimensionality reduction clustering, and senescent immune  
818 cells were evaluated on the cell subpopulations. Hierarchical clustering was used to verify the  
819 effect of different cell subpopulations and gene characteristics on patients receiving neoadjuvant  
820 therapy before surgery to evaluate.

## 821 **Animal experiments.**

822 The animal experiments in this study were conducted with the approval of the Animal  
823 Ethics Committee of Sun Yat-sen University and the Institutional Animal Care and Use  
824 Committee at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences  
825 (CAS). For all animal experiments, mice were housed under controlled conditions of ~50%  
826 humidity, ~25 °C temperature and a 12h light/dark cycle. Isoflurane was used for anaesthesia. At  
827 the end of all experiments, animals were euthanized under CO<sub>2</sub> anaesthesia.

## 828 **4-NQO-induced mouse HNSCC model.**

829 Female C57 mice (12 months old) were housed and drinking water containing 50 mg/L 4-  
830 NQO was given for 12 weeks. All diet and water were made available ad libitum. Subsequently,  
831 the oral cavities of the mice were examined. 24 mice with lesions were randomly divided into 4  
832 groups. Normal drinking water was given. Two days later, αPD-1 was administered  
833 intraperitoneally at a dosage of 10 mg/kg. Then, mice were euthanized. Tongues were collected  
834 for pathological examination and IF.

## 835 **Establishment of cell lines and tissue culture.**

836 Female C57 mice (6-8 weeks old, weighing 18-20 g) were obtained from Gempharmatech  
837 (Guangdong, China). 4-nitroquinoline 1-oxide (4-NQO) was diluted in drinking water to a final  
838 concentration of 50 mg/L for the animals, with weekly replacements. After 12 weeks, all animals  
839 were returned to normal water until week 28. At week 28, animals were euthanized for tissue  
840 extraction. Lesions were dissected, and cells were isolated to establish the 4MOC cell line.

#### 841 **SA- $\beta$ -gal staining**

842 Fresh tissues were fixed in 10% neutral buffered formalin (NBF) for 3–4 h and then  
843 transferred to 30% sucrose overnight. Tissues were then embedded in cryo-embedding medium  
844 (OCT) and cryosectioned at 5  $\mu$ m for staining of SA- $\beta$ -gal (pH 6.0) at 37  $\square$ °C for 16–24 h in SA-  
845  $\beta$ -gal staining solution (40 mM citric acid in sodium phosphate buffer, 5 mM  $K_4[Fe(CN)_6] \cdot 3H_2O$ ,  
846 5 mM  $K_3[Fe(CN)_6]$ , 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg ml<sup>-1</sup> X-gal  
847 dissolved in *N,N*-dimethylformamide). Slides were imaged at 20 $\times$  with a Panoptiq slide scanner  
848 (ViewSiq).

#### 849 **RNA isolation and qRT–PCR**

850 Tissues were collected from euthanized mice and flash-frozen in liquid nitrogen. Tissues  
851 were homogenized using FastPrep-24 homogenizer (MP Biomedicals) and total RNA was  
852 isolated by Trizol extraction according to manufacturer’s specifications (Thermo Fisher). Total  
853 RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher) and 1  $\mu$ g of total  
854 RNA used to generate cDNA via the Transcriptor First Strand cDNA synthesis kit (Roche)  
855 according to the manufacturer’s specifications. Gene expression changes in *(Cdkn2a) p16<sup>Ink4a</sup>*,  
856 *(Cdkn1a) p21<sup>Cip1</sup>* were quantified by qRT–PCR reactions using 20  $\mu$ l reaction volumes and a  
857 StepOne thermocycler (Thermo Fisher) with input of 50 ng total RNA per reaction. For each  
858 sample, reactions were performed in duplicate. Data were analysed by the  $\Delta\Delta$ Ct method and  
859 expression was normalized to *Gapdh*.

860 **Quantitation of 8-OHdG DNA lesions**

861 Tissues from mice were analysed for 8-OHdG levels using the ELISA kit (Abcam)  
862 according to manufacturer's specifications.

863 **Immunoblotting**

864 Snap-frozen livers from mice were incubated in RIPA buffer (Thermo-Fisher) on ice for 30  
865 min after being homogenized with a FastPrep-24 homogenizer. Samples were centrifuged at  
866 17,000g for 15 min at 4 °C. Supernatant was resuspended in 2× SDS loading buffer and 50 µg  
867 of total protein run on a 4–15% SDS–PAGE gel (Bio-Rad) before being transferred to  
868 nitrocellulose membrane. Membranes were blocked for 1 h in 10% milk TBS-T solution at room  
869 temperature before incubation in anti-γH2AX (Novus Biologicals, NB100-384, 1:2,000) and  
870 anti-GAPDH (Abcam, ab8425, 1:5,000) antibody at 4 °C overnight. After washing, samples  
871 were incubated in either horse anti-mouse HRP (Cell Signaling Technology, 7076S) or goat anti-  
872 rabbit HRP secondary antibody (Thermo-Fisher, 656120, 1:2,000) in 5% milk TBS-T solution  
873 for 3 h before washing and visualization with ECL (Thermo-Fisher).

874 **TIL isolation and flow cytometry**

875 Tumors were dissected, minced, and resuspended in complete media (DMEM with 10%  
876 FBS and 1% antibiotics) supplemented with Collagenase-D (1 mg/mL; Roche) and incubated at  
877 37 °C for 30 min with shaking to form a single-cell suspension. Tissue suspensions were washed  
878 with fresh media and passed through a 100-µm strainer. Samples were washed with PBS and  
879 immediately processed for live/dead cell discrimination using BD Horizon™ Fixable Viability  
880 Stain 510. Cell surface staining was done for 30 min at 4 °C with the following antibodies: CD45  
881 (30-F11) (1:100), CD3 (145-2C11) (1:400), CD8a (53-6.7) (1:100), CD4 (RM4-4) (1:400),  
882 NK1.1 (PK136) (1:400), CD62L (MEL-14) (1:200) and CD44 (IM7) (1:100). All flow cytometry

883 data acquisition was done using Beckman Cytexpert and analyzed using FlowJo software  
884 (v10.8.1).

### 885 **Immunofluorescence and image quantification**

886 Briefly, tissues were harvested, fixed, and paraffin embedded. Slides were stained for P16,  
887 P21, CD4, CD8a, CCR7, PAN-CK, LCK, CD62L and S100A11 antibodies (Supplementary  
888 Materials). Quantification of immune infiltration was done using QuPath, an open-source  
889 software for digital pathology image analysis. For the quantification, at least three regions of  
890 interest (ROI) were selected for each condition and the percentage of positive cells was  
891 calculated.

### 892 **DNA sequencing and genomic signature analysis**

893 Raw sequencing data were aligned to the mm10 reference genome using BWA. Somatic  
894 mutations were identified by comparing the sequencing data from each cancer sample to the  
895 sequencing data from a normal tissue derived from the tail of one of the mice (all mice were  
896 genetically identical). To ensure robustness of the results, a consensus variant calling strategy  
897 was leveraged in which somatic mutations were identified using three independent  
898 bioinformatics tools: Strelka2, Varscan2, and GATK4 Mutect2. Somatic mutational profiles  
899 were derived using the immediate sequencing context by evaluating the base 5' and the base 3' to  
900 each single point mutation.

901

### 902 **Data availability**

903 All data associated with this study are present in the paper or the Supplementary Materials.  
904 The raw sequence data including single-cell sequencing, TCR/BCR sequencing of human, as  
905 well as RNA and ATAC sequencing of CD4 naïve T cells datasets generated and analyzed

906 during the current study have been deposited in Genome Sequence Archive (Genomics,  
907 Proteomics & Bioinformatics 2021) with accession code PRJCA027702 and PRJCA028161.

908

## 909 **Methods References**

- 910 65. Nolan, S. *et al.* A large-scale database of T-cell receptor beta (TCR $\beta$ ) sequences and binding associations  
911 from natural and synthetic exposure to SARS-CoV-2. Preprint at <https://doi.org/10.21203/rs.3.rs-51964/v1> (2020).
- 912 66. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis.  
913 *Genome Biol* **19**, 15 (2018).
- 914 67. Polański, K. *et al.* BBKNN: fast batch alignment of single cell transcriptomes. *Bioinformatics* **36**, 964–965  
915 (2020).
- 916 68. Traag, V. A., Waltman, L. & Van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected  
917 communities. *Sci Rep* **9**, 5233 (2019).
- 918 69. Huang, Z. *et al.* Effects of sex and aging on the immune cell landscape as assessed by single-cell  
919 transcriptomic analysis. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2023216118 (2021).
- 920 70. Zou, Z. *et al.* A Single-Cell Transcriptomic Atlas of Human Skin Aging. *Developmental Cell* **56**, 383-  
921 397.e8 (2021).
- 922 71. Wang, S. *et al.* A single-cell transcriptomic landscape of the lungs of patients with COVID-19. *Nat Cell*  
923 *Biol* **23**, 1314–1328 (2021).
- 924 72. Zheng, Y. *et al.* A human circulating immune cell landscape in aging and COVID-19. *Protein Cell* **11**,  
925 740–770 (2020).
- 926 73. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting  
927 genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005).

928

929

930

931

932 **Acknowledgments:** We thank all patients and their families for participation during sample  
933 collection. We are grateful to the support of the Clinical Research Design Division and Clinical  
934 Research Center at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The co-author Dr.  
935 Soldano Ferrone sadly passed away on January 10, 2023, at the age of 82, after an 8-week-long  
936 battle with COVID-19. He was the supervisor of Dr. Song Fan during Dr. Fan's post-doctoral  
937 work in his lab at Massachusetts General Hospital (MGH). Due to his constantly invaluable  
938 guidance and suggestions, which greatly helped improve and organize this study, all contributing  
939 authors agree to keep him as a co-author of this manuscript. We thank all the members of the Fan  
940 lab for valuable discussions and help with experimental techniques and analysis of the  
941 manuscript. This work was supported by the Joint Funds of the National Natural Science  
942 Foundation of China (U21A20381), the General Funds of the National Natural Science  
943 Foundation of China (82373452), the Guangdong Natural Science Funds for Distinguished  
944 Young Scholar (2022B1515020061), the Guangdong Basic and Applied Basic Research  
945 Foundation (2021A1515220138), the Guangzhou Basic Research Program Jointly Funded by  
946 Municipal Schools (Institutes) (202201020367), the Fundamental Research Funds for the Central  
947 Universities, Sun Yat-sen University (16ykpy10), the Fundamental Research Funds for the  
948 Central Universities, Sun Yat-sen University (19ykzd20), the General Funds of the National  
949 Natural Science Foundation of China (32071451), the Guangdong Provincial Pearl River Talents  
950 Program (2021QN02Y747), the Shenzhen Science and Technology Program  
951 (RCYX20210706092100003), and by the Shenzhen Medical Research Funds grant (A2303005).

952

953 **Author contributions:** X.W., S.F., X.F., F.X., N.L., J.W. and E.D. designed the study and  
954 wrote the manuscript, S.F., X.F., F.X. and X.W. supervised the study. Single-cell RNA and




955 T/BCR sequencing, RNA-Seq and ATAC-Seq involves library preparation and data analysis  
956 by N.L., J.W., E.D., T.C, Q.L. and J.Z., B.W., J.W., E.D., X.D., S.F., T.C and Y.Z. collected  
957 patient samples and analyzed clinical data. S.F., N.L., J.W. and E.D. performed experiments  
958 and interpreted the data. All authors critically revised the paper.

959 **Competing interests:** The authors declare that they have no competing interests.

# 1                    **Reversing Immunosenescence with Senolytics to Enhance Tumor**


## 2    **Immunotherapy**

3            Niu Liu<sup>1,2,3#</sup>, Jiaying Wu<sup>1,2#</sup>, Enze Deng<sup>4,5#</sup>, Jianglong Zhong<sup>1,2#</sup>, Bin Wei<sup>1,2#</sup>, Tingting Cai<sup>1,2#</sup>,  
4            Xiaohui Duan<sup>6</sup>, Sha Fu<sup>7</sup>, David O. Osei-Hwedieh<sup>8</sup>, Ou Sha<sup>9</sup>, Yunsheng Chen<sup>1,2,3</sup>, Xiaobin Lv<sup>10</sup>,  
5            Yingying Zhu<sup>11</sup>, Lizao Zhang<sup>1,2</sup>, Hsinyu Lin<sup>1,2</sup>, Qunxing Li<sup>1,2</sup>, Peichia Lu<sup>1,2</sup>, Jiahao Miao<sup>1,2,3</sup>,  
6            Teppei Yamada<sup>12</sup>, Lei Cai<sup>13</sup>, Hongwei Du<sup>14</sup>, Sylvan C. Baca<sup>8</sup>, Qingpei Huang<sup>4</sup>, Soldano Ferrone<sup>†</sup>  
7            , Xinhui Wang<sup>15\*</sup>, Fang Xu<sup>3,16,17\*</sup>, Xiaoying Fan<sup>4,18\*</sup>, Song Fan<sup>1,2\*</sup>




9 **Fig. 1 The results of the Phase II clinical trial (OOC-001) and scRNA-Seq data indicate that**  
10 **MPR patients demonstrate increased diversity in immune response-related cell subtypes**  
11 **and exhibit decreased expression of senescence markers.**

12 **a**, Waterfall plot depicting the treatment response of patients in the HNSCC neoadjuvant clinical  
13 trial OOC-001 (NCT04718415, n=50). **b**, Pie charts depicting radiological and pathological  
14 response rates in OOC-001. **c**, The changes and proportional statistics of TNM staging after  
15 treatment for primary tumors in different patients. **d**, Schematic overview of the experimental  
16 design and analytical workflow. **e**, UMAP plot of the immune cells that passed quality control.  
17 Immune cell clusters are annotated and marked by color code. **f**, Prevalence of each single-cell  
18 cluster (column) in all samples (n = 7) from different groupings of tissue (rows). Green dots  
19 represent tumors samples, pink dots represent peripheral blood samples of pre-treatment (P0),  
20 and red dots represent peripheral blood samples of post-treatment (P1). **g**, Estimation of size and  
21 diversity of TCR repertoires for T cell clusters and BCR repertoires for B cell clusters between  
22 MPR and noMPR groups in tumors. The number of TCR and BCR clonotypes estimated by  
23 Chao1 (Materials and Methods) illustrates the predicted theoretical clonotype diversity. Data are  
24 expressed as mean  $\pm$  s.e.m. **h**, Quantifications of immunofluorescent staining for senescent  
25 markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts  
26 (Cohort1 n=50, Cohort2 n=61). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .






28 **Fig. 2 Patient responses to immunotherapy are associated with the expression of IAGs in**  
29 **both T and B cell subsets, as well as the interaction of IGF1<sup>+</sup> M $\phi$  with T and B cells.**  
30 **a**, The IAGs significantly enriched in all immune cells in peripheral blood of frail elderly people  
31 (GSE157007) and old people (PRJCA002856). **b**, The Ridge plot of IAGs score analysis for  
32 major T cells clusters. **c**, Dot plot of intersection genes of HNSCC T cell DEGs and IAGs  
33 between MPR and noMPR groups. **d**, UMAP of T cells from 4 paired tumor and blood samples  
34 (12 samples total), highlighting shared clones between tumors (green) and P0 (pink, pre-  
35 treatment blood) and P1 (red, post-treatment blood). **e**, Shared clonal cells ratio between tumor  
36 (green) and P0 (pink, pre-treatment blood) and P1 (red, post-treatment blood) T cells from 4  
37 paired tumor and blood samples. **f**, Paired TCR results Shows the overall number of TCR clones  
38 (upper row), and the status of single clones after normalization (lower row). **g**,  
39 Immunohistological staining quantifications of CD4 and S100A11 in HNSCC patients of two  
40 cohorts (n=12 per group). **h**, Low expressions of S100A11 and high proportion of CD4 Naïve T  
41 cells and memory B cells were significant associated with better OS. **i**, Hierarchical clustering  
42 tree shows different models distinguish pathological responses of patients following the  
43 combination therapy before surgery. T&B cells mean using the proportional distribution of T and  
44 B cells and representative genes as a model to predict the patient's response. T cells alone or B  
45 cells alone means using the proportional distribution of T cells or B cells and representative  
46 genes as a model to predict patient response to treatment (the inner circle is the HNSCC patients'  
47 number, and the outer circle is the cophenetic distance result to evaluate the effect). **j**, The  
48 cellular compositions of myeloid cell clusters in P0 and P1 between MPR and noMPR groups in  
49 HNSCC. **k**, Proportion of tumor-infiltrating IGF1<sup>+</sup> M $\phi$  was inversely correlated to the proportion  
50 of tumor infiltrating CCR7<sup>+</sup>CD4 Naïve T and CD27<sup>-</sup> Memory B in HNSCC. Pearson correlation  
51 (two-sided).




53 **Fig. 3 The combination of Dasatinib and Quercetin with  $\alpha$ PD-1 enhances therapeutic**  
54 **efficacy in a chemically induced HNSCC mouse model by alleviating immunosenescence.**  
55 **a**, Representative images of SA- $\beta$ -gal and eosin staining for senescence markers in tumors and  
56 adjacent normal tissues from HNSCC patients, along with paired quantitative analysis of SA- $\beta$ -  
57 gal positive areas. Scale bar, 50  $\mu$ m. **b**, Flowchart for Inducing HNSCC in C57 mice by adding  
58 4NQO to drinking water (Top). Schematic representation of different groups in 4NQO-induced  
59 mice, including Isotype intraperitoneal injection (Isotype),  $\alpha$ PD-1 intraperitoneal injection ( $\alpha$ PD-  
60 1),  $\alpha$ PD-1+Cisplatin intraperitoneal injection ( $\alpha$ PD-1+CP),  $\alpha$ PD-1 intraperitoneal injection plus  
61 Dasatinib+Quercetin oral gavage ( $\alpha$ PD-1+DQ). Isotype or  $\alpha$ PD-1 was administered at 200  $\mu$ g per  
62 mouse, Cisplatin at 3 mg/kg, given on days 0, 7, and 14 of the experiment; Dasatinib (5 mg/kg)  
63 and Quercetin (50 mg/kg) were administered on days 0, 3, 7, 10 and 14 (Bottom). **c**,  
64 Immunohistological staining and staining area quantifications of SASP marker P16 and tumor  
65 marker Pan-CK in the 4NQO induced HNSCC mice. Scale bar, 10  $\mu$ m. **d**, Representative images  
66 of tongue of mice after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment. White  
67 arrows indicate tumor-like nodules (left); Dysplasia area quantifications of the mice treated with  
68 Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ (n=6 per group) (right). **e**, Mouse over survival  
69 (Surviving mice/Total number of mice x 100%) after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  
70  $\alpha$ PD-1+DQ treatment (n=6 per group). **f**, Flow cytometry analysis of the expression of the  
71 Senescence marker  $\beta$ -gal in immune cells within mouse tumors after receiving Isotype,  $\alpha$ PD-1,  
72  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=5 per group). **g**, Scatter plot showing the correlation  
73 between the expression level of  $\beta$ -galactosidase in immune cells and the survival time of mice. **h**,  
74 Flow cytometry analysis of CD4<sup>+</sup>, CD8<sup>+</sup>, and B cell proportions in 4-NQO mouse tumors after  
75 receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **i**, Expression  
76 of senescence markers (*p16<sup>Ink4a</sup>* and *p21<sup>Cip1</sup>* mRNA) in CD4<sup>+</sup> TILs in mouse tumors after



77 receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **j**, Flow  
78 cytometry analysis of CD4<sup>+</sup> Naïve T cells proportions in mouse tumors after receiving Isotype,  
79  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **k**, Representative images and  
80 quantifications of immunofluorescent staining for CD4<sup>+</sup>CD62L<sup>+</sup> T cells after receiving Isotype,  
81  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). The statistical analysis was  
82 performed using t test (a), one-way ANOVA (c, d, f, h, i, j, k) and log-rank test (e). *P* values are  
83 shown, and error bars indicate the mean  $\pm$  SEM.



85 **Fig. 4 Senolytics combined  $\alpha$ PD-1 improve the efficacy of solid tumors in *Ercc1*<sup>+/-</sup>**  
86 **transgenic aging models by reducing SASP and increasing tumor-infiltrating CD4<sup>+</sup> naïve T**  
87 **cells. a**, Schematic diagram of orthotopic transplantation of tumor cells derived from the 4-NQO  
88 model into the tongues of *Ercc1*<sup>+/-</sup> transgenic mice. **b**, Representative photos of 3-month-old  
89 *Ercc1*<sup>+/-</sup> mice (*Ercc1*<sup>+/-</sup> 3m), 9-month-old *Ercc1*<sup>+/-</sup> mice (*Ercc1*<sup>+/-</sup> 9m), and 20-month-old wild  
90 type (WT 20m) C57 mice. **c**, Levels of 8-OHdG in spleens from *Ercc1*<sup>+/-</sup> 3m, *Ercc1*<sup>+/-</sup> 9m and  
91 WT 20m mice (n=6 per group). **d**, Splenic weights normalized to body weight of *Ercc1*<sup>+/-</sup> 3m,  
92 *Ercc1*<sup>+/-</sup> 9m and WT 20m mice (n=6 per group). **e**, Immunoblot detection of  $\gamma$ H2AX in spleen,  
93 heart, liver and lung from 10-month-old WT or 10-month-old *Ercc1*<sup>+/-</sup> (*Ercc1*<sup>+/-</sup>) mice. **f**,  
94 Representative images of H&E staining for 4N-MS1 tongue orthotopic transplant tumors. **g**, C57  
95 mice were implanted with 5 $\times$ 10<sup>5</sup> 4N-MS1 cells into the tongue. Administration of different drug  
96 treatments around the 7th day after 4N-MS1 implantation. Tumor growth curve showing the  
97 tumor size after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group).  
98 **h**, Multiplex bead-based protein analysis of lysate of mouse tongue tumor after receiving Isotype,  
99  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=3 per group). **i**, Flow cytometry analysis of  
100 CD4<sup>+</sup> Naïve T cells proportions in mouse tumors after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  
101  $\alpha$ PD-1+DQ treatment (n=6 per group). **j**, Representative images and quantitative analysis of  
102 P21 and CD62L staining in 4N-MS1 tongue orthotopic transplant tumors. (n=6 per group). **k**,  
103 Tumor growth curves for MB49 and E0771 transplant models after receiving Isotype,  $\alpha$ PD-1,  
104  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). The statistical analysis was performed  
105 using one-way ANOVA (c, d, h, j) and log-rank test (g, k). *P* values are shown, and error bars  
106 indicate the mean  $\pm$  SEM.




107  
108 **Fig. 5 ATAC-Seq and RNA-Seq analyses of CD4<sup>+</sup> naive T cells provide evidence for the**  
109 **potential of αPD-1+DQ in the regulation of immunosenescence. a**, Pattern diagram of cell  
110 sorting, as well as combined sequencing with ATAC-Seq and RNA-Seq. **b**, Heatmap illustrating  
111 differences in the expression levels of T cell di-related genes among different groups. **c**, DEGs  
112 (Log<sub>2</sub>Foldchages > 0.5) of CD4 naive T cells in tumors between αPD-1 and DQ and isotype

113 groups enriched GO terms. **d**, ATAC-seq tracks showing the representative genes chromatin  
114 accessibility in the *Ccr7* and *S100a11* loci for CD4 naïve T cells in mouse tumors from isotype,  
115  $\alpha$ PD-1 and DQ, and  $\alpha$ PD-1 groups. **e**, RNA-seq and ATAC-seq detected GO terms that were  
116 simultaneously enriched in the  $\alpha$ PD-1 and DQ and isotype groups. **f**, Expression of *Ccr7*, *Lck*,  
117 *Cfd*, *S100a11*, *p16<sup>Ink4a</sup>*, *p21<sup>Cip1</sup>* in CD4<sup>+</sup> naïve T cells in mouse tumors after receiving Isotype,  
118  $\alpha$ PD-1 or  $\alpha$ PD-1+DQ treatment (n=6 per group). **g**, Flow cytometry analysis of CCR7 and  
119 LCK in CD4<sup>+</sup> Naïve T cells proportions in mouse tumors after receiving Isotype,  $\alpha$ PD-1 or  $\alpha$ PD-  
120 1+DQ treatment (n=6 per group). **h**, Representative images of CCR7 and LCK staining in 4N-  
121 MS1 tongue orthotopic transplant tumors. The statistical analysis was performed using one-way  
122 ANOVA (**f**, **g**). *P* values are shown, and error bars indicate the mean  $\pm$  sem.




a


### Study Design of COIS-01




b




c




d



f



e




124 **Fig. 6 The Phase II clinical trial COIS-01 validated the safety and efficacy of combining**  
125 **senolytic drugs with anti-PD-1 therapy. a,** Schematic representation of the clinical trial (COIS-  
126 01) investigating the combination of ICIs with senolytics as neoadjuvant therapy for HNSCC. **b,**  
127 The waterfall chart displays the clinical characteristics of 24 patients in the COIS-01 trial. **c,**  
128 Representative imaging, HE pathology, and intraoral photographs of two pCR patients from  
129 COIS-01. MM represents the masseter muscle, MB represents the mandible, and the tumor area  
130 is indicated by the circled region. Scale bar, 50  $\mu$ m. **d,** The radar chart shows the proportions of  
131 various types of TRAEs in two clinical trials. **e,** Comparison of TRAEs between the COIS-01  
132 and OOC-001 clinical trials. **f,** Representative images and quantifications of immunofluorescent  
133 staining for CCR7<sup>+</sup> Naïve T cells before and after treatment (n=□24 per group). The statistical  
134 analysis was performed using t test (**f**). *P* values are shown, and error bars indicate the mean  $\pm$   
135 sem.

136

137


138






140 **Extended Data Fig. 1 The trial design and outcomes of OOC-001.**

141 **a**, Trial flow diagram. **b**, Representative pre- and post-treatment intraoral photographs, H&E  
142 staining, and MRI images for MPR and noMPR patients. Scale bar = 50  $\mu$ m. **c**, The changes and  
143 proportional statistics of TNM staging after treatment for lymph nodes in different patients. **d**,  
144 Scatter plot depicts the pathological response and radiographic response of the primary tumor  
145 after neoadjuvant treatment in the same patient (left), and the radiographic response of the  
146 primary tumor and lymph node metastasis in the same patient after neoadjuvant treatment (right).  
147 **e**, Pathological response of the primary tumor in patients treated with different cycles during  
148 neoadjuvant therapy (left), radiographic response of the primary tumor in patients treated with  
149 different cycles during neoadjuvant therapy (middle), and all remission include primary tumor  
150 and lymph node metastasis in patients treated with different cycles during neoadjuvant therapy  
151 (right). **f**, The rates of MPR for patients after 2 cycles, 3 cycles, and 4 cycles of treatment, as well  
152 as the rates of Grade 1-2 adverse events and Grade 3-4 adverse events. **g**, Survival curves for  
153 patients in this clinical trial at the 24-month follow-up. **h**, Disease-free survival (DFS) and OS  
154 curves for patients in this clinical trial at the 24-month follow-up.



157 **Extended Data Fig. 2 Dynamic characterization of TCR landscape.**


158 **a**, TCR-seq was performed on T cells from tumors (pre-treatment biopsy tumors), P0 (pre-  
159 treatment blood), and P1 (post-treatment blood) obtained from patients (from top to bottom,  
160 patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). The top 10 clonotype frequencies detected in T  
161 cells that differed most in peripheral blood before and after treatment are shown in serial  
162 peripheral blood (left) and tumor tissue (right). **b**, From left to right represents changes in high  
163 abundance clonotypes in tumors and blood before and after patient treatment, and patients from  
164 top to bottom are SH1, SH2, SH3, SH4, SH5, SH6, SH7. Each circle represents a clonotype. The  
165 diameter of the circle indicates the concentration of the clonotype. Persistent clonotypes are  
166 marked as bright circles, with a single color representing one clonotype. For patients with MPR,  
167 the predominant high-abundance clonotype present in tumors and blood before treatment  
168 remained the predominant high-abundance clonotype after treatment. **c**, Pairwise similarity  
169 (Grantham distance) between the top 50 most common intratumoral TCR CDR3b clones.  
170 Evaluate the similarity between the most common lengths of CDR3b amino acid sequences in  
171 each patient (from top to bottom, patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). Red indicates  
172 the most expanded clone. **d**, Bar plot of TCR and BCR clonotypes across all T cells and B cells  
173 in MPR or noMPR groups from P0, P1 and tumors. One clonotype consists strictly of one paired  
174  $\alpha$ - $\beta$ -chain V(D)J TCR. **e**, Pie chart of the antigen specificity of detected TCRs when considering  
175  $\alpha$ -,  $\beta$ -, and paired strands. CMV, cytomegalovirus; EBV, Epstein-Barr virus; InfluenzaA,  
176 influenza A virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HS, Homo  
177 sapiens antigen; HIV-1, human immunodeficiency virus 1; HCV, hepatitis C virus; YFV, yellow  
178 fever virus; DEV, dengue virus. **f**, Representative immunofluorescence images of senescent  
179 markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts  
180 (Cohort1 n=50, Cohort2 n=61).



183 **Extended Data Fig. 3 Development and validation of IAGs.**


184 **a**, Human immune cell samples from multiple data sets were used for single-cell RNA  
185 sequencing analysis to construct the IAGs. **b**, The IAGs significantly enriched in B cells (middle)  
186 and T cells (right) in peripheral blood of frail elderly people (GSE157007). **c**, The IAGs is  
187 significantly enriched in B cells (middle) and T cells (right) in the peripheral blood of elderly  
188 women (PRJCA002856). **d**, The IAGs is significantly enriched in all immune cells in bone  
189 marrow of older women (GSE141595). **e**, Violin plot of expression of the different all cells IAGs  
190 score in HNSCC tumors between MPR and noMPR groups (left), and in TNBC tumors between  
191 PR and SD groups (right). Black lines with different lengths indicate which two groups were  
192 compared. Wilcoxon signed-rank test.





194 **Extended Data Fig. 4 Anti-tumor reactivity and immunosenescence features of T cell**  
195 **subtypes.**


196 **a**, Violin plot of expression of all T cells IAGs score in HNSCC tumors between MPR and  
197 noMPR groups. Black lines with different lengths indicate which two groups were compared.  
198 Wilcoxon signed-rank test. **b**, Gene Venn diagram of differential genes of T cell subtypes in  
199 tumors between MPR and noMPR groups. **c**, UMAP shows the distribution of T cell and B cell  
200 subtypes in TNBC. **d**, Box plot of the percentage of the T cell clusters in TNBC tumors between  
201 PR and SD groups. The boxed plot on the left of each T cell cluster is the PR group, and on the  
202 right is SD group. Box middle lines, median; box limits, upper and lower quartiles. Black lines  
203 with different lengths indicate which two groups were compared. Wilcoxon signed-rank test. **e**,  
204 Violin plot of expression of all T cells IAGs score in TNBC tumors between PR and SD groups.  
205 Black lines with different lengths indicate which two groups were compared. Wilcoxon signed-  
206 rank test. **f**, The Ridge plot of IAGs score analysis for T cells clusters in TNBC. **g**, Dot plot of  
207 intersection genes of TNBC T cell DEGs and IAGs between PR and SD groups. **h**, DEGs  
208 ( $\text{Log}_2\text{Foldchanges} > 0.5$ ) of CCR7<sup>+</sup> CD4 naïve T cells and CXCL13 CD4 T helper cells between  
209 MPR and noMPR enriched GO terms in tumors. Log-rank test (two-sided). \* $P < 0.05$ ,  
210 \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .






213 **Extended Data Fig. 5 CD4 T cell differentiation pathway.**

214 **a**, Frequency of  $V\alpha/\beta$  gene usage among  $CCR7^+$  CD4 T cells and  $FOXP3^+$  CD4 Treg cells in  
215 tumors and  $CCR7^+$  CD4 T cells in blood (V genes ordered by decreasing frequency in  $CCR7^+$   
216 CD4 T cells in blood). **b**, UMAP embedded CD4 T cell trajectory with mapping of pseudotime  
217 (top left), cell subtype distribution (top right), single-cell transcriptional profiles of each tissue  
218 (bottom left), and different groups (bottom right) sampled in the study. **c**, Pseudotime  
219 distribution diagram of the proportion of CD4 T cells in tumors, the MPR group on the left, the  
220 noMPR group on the right. **d**, Differential genes of CD4 Naïve T cells in tumors and peripheral  
221 blood.



223 **Extended Data Fig. 6 Immunosenescence features of B cells.**

224 **a**, Paired BCR results Shows the overall number of BCR clones (upper row), and the status of  
225 single clones after normalization (lower row). **b**, Gene Venn diagram of differential genes of B  
226 cell subtypes in tumors between MPR and noMPR groups. **c**, Dot plot of intersection genes of  
227 HNSCC B cell DEGs and IAGs between MPR and noMPR groups (upper), and between PR and  
228 SD groups in TNBC. **d**, The dot plot showing DEGs ( $\text{Log}_2\text{Foldchages} > 0.5$ ) of B cells between  
229 MPR and noMPR groups enriched GO terms in tumors. **e**, GO terms enriched in CD27<sup>+</sup>Memory  
230 B cells in tumors between MPR and noMPR groups. adjusted p value  $< 0.05$ . **f**, Heatmap  
231 showing the expression of ligand-receptor pairs highly expressed in T cell subtypes and B cell  
232 subtypes in tumor. **g**, Immunohistological staining quantifications of CD27 and S100A11 in  
233 HNSCC patients of two cohorts (MPR n=12, noMPR n=14).




235 **Extended Data Fig. 7 Dynamics of myeloid cell subtypes after neoadjuvant**  
236 **chemoimmunotherapy.**

237 **a**, UMAP embedding myeloid cell trajectory with mapping of pseudotime. **b**, UMAP plots  
238 showing the distributions myeloid cells between MPR and noMPR groups. **c**, The proportion of  
239 myeloid cells in different tissues. **d**, Gene similarity between IGF1<sup>+</sup> M $\phi$  and myeloid cell  
240 clusters from peripheral blood. **e**, UMAP showing the distribution of myeloid cell clusters (left),  
241 embedding the single-cell transcriptional profiles of myeloid cell from each tissue sampled (top  
242 right), and from different groups (bottom right) in TNBC. **f**, The cellular compositions of  
243 myeloid cell clusters in tumors and peripheral blood between PR and SD groups in TNBC. **g**,  
244 Violin plot of six key SASP expression of the IAGs score in myeloid cell clusters in tumors (left)  
245 and peripheral blood (right). **h**, Violin plot of six key SASP expression of the IAGs score in  
246 myeloid cell clusters in tumors (left) and peripheral blood (right) from TNBC. **i**, Low  
247 expressions of IGF1<sup>+</sup> M $\phi$  signature gene were significant associated with better OS and DFS.  
248 Log-rank test (two-sided).


249





251 **Extended Data Fig. 8 The effect of Senolytics combined with  $\alpha$ PD-1 on TIME of 4-NQO**  
252 **mice.**


253 **a**, Representative images of tongue sections from mice, fed with 4-nitroquinoline-1-oxide (4-  
254 NQO)-containing drinking water for 12, 20, and 28 weeks, stained with hematoxylin and eosin  
255 (HE). Scale bar, 50 $\mu$ m. **b**, Images of tongue of mice after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP  
256 or  $\alpha$ PD-1+DQ treatment (n=6 each group). Red arrows indicate tumor-like nodules. **c**, Line  
257 graph illustrating the change in mouse body weight over time after receiving Isotype,  $\alpha$ PD-1,  
258  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **d**, Flow cytometry gating strategy for  
259 assessing the proportions of CD4<sup>+</sup>, CD8<sup>+</sup>, as well as T cell subtypes. **e-g**, Flow cytometry  
260 immunophenotyping of splenic cells, bone marrow Cells and blood showing the frequencies of  
261 CD4<sup>+</sup>, CD8<sup>+</sup> and B220<sup>+</sup> cells in mice after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ  
262 treatment (n=6 each group). **h**, Senescence markers *p16* and *p21* expression in CD8<sup>+</sup> TILs from  
263 the mice treated with Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ (n=6 per group).





265 **Extended Data Fig. 9  $\alpha$ PD-1+DQ enhanced the anti-tumor effect in breast and bladder**  
266 **cancer xenograft models.**

267 **a-b**, The whole-exome sequencing (WES) of 4N-MS1 cells reveals the classification of Single  
268 Nucleotide Variants (SNV Class) and the top 10 genes with the highest mutation frequencies. **c**,  
269 Tumor images and survival curves for the MB49 transplant model after receiving Isotype,  $\alpha$ PD-1,  
270  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **d**, The survival curves for the E0771  
271 transplant model after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per  
272 group). **e-f**, Representative immunofluorescence images and statistical analysis of the senescent  
273 marker P21 and the Naïve cell marker CD62L in MB49 and E0771 tumor xenografts after  
274 receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=5 per group).



276 **Extended Data Fig. 10 Transcriptomic and epigenetic dynamics of CD4 naïve T cells**  
277 **following the  $\alpha$ PD-1+DQ therapy.**

278 **a**, Volcano plot of differentially expressed genes between  $\alpha$ PD-1+DQ and Isotype groups (left),  
279  $\alpha$ PD-1 and Isotype groups (middle),  $\alpha$ PD-1+DQ and  $\alpha$ PD-1 groups (right). **b**, DEGs  
280 (Log2Foldchanges > 0.5) of CD4 naïve T cells in tumors between  $\alpha$ PD-1 and Isotype groups  
281 enriched GO terms. **c**, Proportions of the ATAC-seq peak regions representing various genome  
282 annotations identified in Isotype,  $\alpha$ PD-1+DQ and  $\alpha$ PD-1 groups. **d**, The heatmap of different  
283 annotated genes in Isotype,  $\alpha$ PD-1 and  $\alpha$ PD-1+DQ groups from ATAC-seq. **e**, Venn diagram of  
284 peaks of CD4 naïve T cells in Isotype,  $\alpha$ PD-1 and  $\alpha$ PD-1+DQ groups. **f**, ATAC-seq tracks  
285 showing the representative genes chromatin accessibility in the *Lck*, *Cfd*, and *Slfn2* loci for CD4  
286 naïve T cells in Isotype,  $\alpha$ PD-1+DQ and anti-PD-1 groups. **g**, RNA-seq and ATAC-seq detected  
287 GO terms that were simultaneously enriched in the  $\alpha$ PD-1 group and Isotype group (left) and GO  
288 terms that were enriched in open chromatin regions unique to the  $\alpha$ PD-1+DQ group and  $\alpha$ PD-  
289 1group (right).

290